FRAGMENT AND GEOMETRY AWARE TOKENIZATION OF MOLECULES FOR STRUCTURE-BASED DRUG DESIGN USING LANGUAGE MODELS

Anonymous authors

Paper under double-blind review

ABSTRACT

Structure-based drug design (SBDD) is crucial for developing specific and effective therapeutics against protein targets but remains challenging due to complex proteinligand interactions and vast chemical space. Although language models (LMs) have excelled in natural language processing, their application in SBDD is underexplored. To bridge this gap, we introduce a method, known as Frag2Seq, to apply LMs to SBDD by generating molecules in a fragment-based manner in which fragments correspond to functional modules. We transform 3D molecules into fragmentinformed sequences using SE(3)-equivariant molecule and fragment local frames, extracting SE(3)-invariant sequences that preserve geometric information of 3D fragments. Furthermore, we incorporate protein pocket embeddings obtained from a pre-trained inverse folding model into the LMs via cross-attention to capture protein-ligand interaction, enabling effective target-aware molecule generation. Benefiting from employing LMs with fragment-based generation and effective protein context encoding, our model achieves the best performance on binding vina score and chemical properties such as QED and Lipinski, which shows our model's efficacy in generating drug-like ligands with higher binding affinity against target proteins. Moreover, our method also exhibits higher sampling efficiency compared to atom-based autoregressive and diffusion baselines with at most $\sim 300 \times$ speedup.

1 Introduction

Structure-based drug design (SBDD) is a critical method in medicinal chemistry that involves the design and optimization of molecules to interact specifically and effectively with biological targets, typically protein pockets (Anderson, 2003). This approach is fundamental in developing new therapeutic drugs as it allows for more precise interaction with biological systems, potentially reducing side effects and increasing efficacy. Traditionally, SBDD relies heavily on high-throughput virtual screening (Lyne, 2002; Shoichet, 2004) and experimental validation. These processes are not only time-consuming and labor-intensive but also require substantial financial resources.

In recent times, machine learning has emerged as a promising approach for advancing scientific endeavors (Zhang et al., 2023b; Liu et al., 2021; Luo & Ji, 2022). SBDD poses great challenges to machine learning models as it requires the model to capture complicated protein-ligand interaction while improving the drug-likeness of designed molecules. Earlier works have tried to use autoregressive models (Luo et al., 2021; Peng et al., 2022) and diffusion models (Guan et al., 2022; 2023) to encode context information and generate molecules. However, these models only consider atom-wise generation, and diffusion models typically need thousands of steps to generate, which results in an inefficient generation. Another line of work chooses to generate molecules based on molecular fragments (Zhang et al., 2022; Zhang & Liu, 2023), but it often requires a complicated pipeline involving several neural networks to choose and link fragments.

Recently, language models (LMs) have demonstrated substantial promise in various fields due to their robust data processing and generative capabilities (Vaswani et al., 2017; Devlin et al., 2018; Brown et al., 2020; Gu et al., 2021). These models, especially large language models (LLMs) (Zhang et al., 2024; Touvron et al., 2023; Achiam et al., 2023; Chowdhery et al., 2023), excel in learning complex patterns and producing coherent outputs, which makes them ideal candidates for advanced tasks in

natural language processing and beyond. Despite these strengths, the application of LMs to SBDD remains largely unexplored. LMs offer notable advantages, such as handling large datasets with prominent efficiency over diffusion-based methods, learning from massive biological and chemical texts for diverse potential tasks, and generating drug-like molecules with high specificity. However, challenges persist, particularly the need to adapt LMs to process geometric graph structures of molecular data, which are fundamentally different from textual data. Moreover, it's promising to consider how to apply LMs to perform fragment-based generation, which can generate more realistic substructures and reduce generation steps to improve efficiency. Additionally, ensuring that these models can accurately simulate the physical and chemical properties of molecules remains a significant hurdle, and it's also crucial to consider how to encode protein context information in LMs to effectively capture protein-ligand interaction in order to generate molecules that can bind to target proteins. Addressing these challenges could unlock the transformative potential of LMs in SBDD, leading to more efficient and effective drug discovery processes.

In this work, we propose to employ LMs to generate molecules in a fragment-based manner for the SBDD task. To achieve this, we developed a novel approach to convert 3D molecules into fragment-informed sequences by constructing SE(3)-equivariant molecule and fragment local frames and then extracting SE(3)-invariant sequences that contain the SE(3)-invariant coordinates and orientations of 3D fragments. To consider protein conditions, we use an existing pre-trained inverse folding model to extract the embedding of protein pockets and incorporate this information into LMs by cross-attention mechanism. In this way, our method enables the usage of powerful LMs in the target-aware molecule generation while keeping geometric information in sequence conversion. Our experimental results evidence these advantages, outperforming strong baselines in both efficacy and efficiency.

2 RELATED WORKS

Structure-Based Drug Design. Structure-based drug design aims to generate molecules that can bind to the given protein pocket. LiGAN (Ragoza et al., 2022) uses an atomic density grid to represent protein-ligand structures. The atom type, positions, and bonds are constructed from generated density grids. Then, the following works (Luo et al., 2021; Peng et al., 2022; Liu et al., 2022) generate molecules using autoregressive models. For example, GraphBP (Liu et al., 2022) uses normalizing flow to generate each atom's relative position in an equivariant way by constructing local coordinate systems. Pocket2Mol (Peng et al., 2022) also considers bond generation to improve the structure validity. Compared with autoregressive models, diffusion-based SBDD models (Schneuing et al., 2022; Guan et al., 2022; 2023) can generate all atoms of molecules in a one-shot way. For example, DiffSBDD (Schneuing et al., 2022) denoises all atom positions and types from a Gaussian distribution. To generate more realistic substructures, FLAG (Zhang et al., 2022) and DrugGPS (Zhang & Liu, 2023) adopt fragment-based methods to generate molecules motif-by-motif. For those methods using language models, TamGen (Xia et al., 2024) only generates SMILES, and Lingo3DMol (Feng et al., 2024) generates fragment-based SMILES then predicts molecule coordinates. They both need pre-training on millions of SMILES or 3D molecule structures to achieve good results.

Language Models for Chemistry. Drawing inspiration from the success of LMs in NLP and beyond, chemical language models (CLMs) emerge as a competent way for representing molecules (Bran & Schwaller, 2023; Janakarajan et al., 2023; Bajorath, 2024; Zhang et al., 2024). Variants of LMs have been adapted for molecular science, producing a variety of works including DrugGPT (Li et al., 2023b), DrugChat (Liang et al., 2023), MoleculeSTM (Liu et al., 2023a), ChemGPT (Frey et al., 2023) MolGPT (Bagal et al., 2021), MolReGPT (Li et al., 2023a), MolT5 (Edwards et al., 2022), MoleculeGPT (Zhang et al., 2023a), InstructMol (Cao et al., 2023), and many others (Luo et al., 2022; Mao et al., 2023b; Haroon et al., 2023; Blanchard et al., 2023). CLMs learn the chemical vocabulary and syntax used to represent molecules. All inputs including chemical structures and property syntax should be converted into a sequence form and tokenized for compatibility with language models. Commonly, SMILES (Weininger, 1988) is used for this sequential representation, although other formats like SELFIES (Krenn et al., 2019), atom type strings, and custom strings with positional or property values are also viable options. To learn representations, CLMs are usually pre-trained on extensive molecular sequences through self-supervised learning. Subsequently, models are fine-tuned on more focused datasets with desired properties, such as activity against a target protein. Most existing CLM works consider chemical structures as well as other modalities such




Figure 1: Illustration of splitting molecules into fragments.

as natural language captions (Bagal et al., 2021; Li et al., 2023a; Edwards et al., 2022; Xie et al., 2023; Chen et al., 2023b; Tysinger et al., 2023; Xu et al., 2023; Chen et al., 2023a; Pei et al., 2023; Liu et al., 2023b; Wang et al., 2023), while some focus on pure text of chemical literature (Luo et al., 2022) or molecule strings (Haroon et al., 2023; Mao et al., 2023b; Blanchard et al., 2023; Mazuz et al., 2023; Fang et al., 2023; Kyro et al., 2023; Izdebski et al., 2023; Yoshikai et al., 2023; Wu et al., 2023; Mao et al., 2023a). Notably, all these works solely consider 2D molecules for representation learning and downstream tasks, overlooking 3D geometric structures which is crucial in many chemical predictive and generative tasks. In order to use pivotal 3D information, another line of work incorporate geometric models such as GNNs in parallel with the CLM (Xia et al., 2023; Zhang et al., 2023a; Cao et al., 2023; Liang et al., 2023; Liu et al., 2023a; Frey et al., 2023), which requires additional design and training techniques to mitigate alignment issues. However, no existing work uses LMs to directly generate 3D ligands in structure-based drug design.

3 METHODS

In this section, we describe how to convert 3D molecules into sequences in a fragment-based manner, which can be effectively processed by language models. In Section 3.1, we formally introduce the problem definition of SBDD. Then, in Section 3.2, we show how to split 3D molecules into 3D fragments. With these 3D fragments, next in Section 3.3, we introduce the way to construct a bijective mapping between 3D fragments and SE(3)-invariant sequences by constructing SE(3)-equivariant molecule and fragment local frames. Finally, in Section 3.4, we describe how to incorporate conditional information of proteins into the language model and the training and generation strategies.

3.1 Problem Definition

Our objective is to design 3D molecules (*i.e.*, ligands) that can effectively bind to a given protein target within its binding pocket while also demonstrating suitable drug-like properties. The 3D geometry of a protein binding pocket is represented as $\mathcal{P} = \{(s_i, b_i)\}_{i=1}^n$, where $s_i \in \mathbb{R}^3$ denotes the 3D Cartesian coordinates of the *i*-th atom and b_i is a one-hot vector that denotes the atom type. Similarly, we represent a ligand as $\mathcal{M} = \{(v_j, z_j)\}_{i=1}^m$, where $v_j \in \mathbb{R}^3$ and z_j denote coordinates and atom type, respectively. Our goal is to learn a conditional generative model that captures the conditional probability $p(\mathcal{M}|\mathcal{P})$ from the training protein-ligand pairs.

3.2 3D MOLECULE FRAGMENTATION

Since we generate molecules in a 3D fragment-based manner, we first need to decompose molecules in the training set into 3D fragments. Specifically, as shown in Figure 1, we split fragments by cutting rotatable chemical bonds that meet three conditions: (1) the bond is not in a ring, (2) the bond type is single, and (3) the degree of the beginning and end atom on the bond is larger than 1. The third condition prevents breaking the functional groups, such as the hydroxy and carboxyl groups. To maintain a canonical order of splited fragments, we further sort fragments based on the order of their appearance in the canonical SMILES representation. More details of canonical order are described in Section 3.3.1. Formally, for a molecule \mathcal{M} , we split it into a set of 3D fragments $\{\mathcal{G}_i = (Z_i, V_i)\}_{i=1}^k$, where Z_i denotes atom type matrix and V_i denotes Cartesian coordinates.

3.3 Fragment-Based 3D Molecule Tokenization

3.3.1 Atom Ordering based on 3D Graph Isomorphism

As the first step in molecule tokenization, we need to transform a molecular (fragment) graph into a 1D sequential representation. Thus we need to establish an order for the atoms of given 3D graphs. To acheive dimension reduction with least information loss, we seek uniqueness in the ordering and




Figure 2: Overview of Frag2Seq pipeline. Atoms in the small molecule are reordered according to the order in canonical SMILES. Then, we split the 3D molecules into 3D fragments and sort them based on the canonical order. Next, we construct SE(3)-equivariant molecule and fragment frames, which are local coordinate systems for molecules and fragments, respectively. Then, we obtain the SE(3)-invariant spherical coordinates (d,θ,ϕ) of each fragment center under the molecule frame and SE(3)-invariant rotation vector (m_x,m_y,m_z) between fragment and molecule frames. Lastly, we concatenate them into sequences. Protein node embeddings are obtained using the ESM-IF1 model and incorporated into the language model via cross-attention.

resort to canonical SMILES (O'Boyle, 2012; Weininger et al., 1989)as a solution. A key property of canonical SMILES is its ability to provide a unique string representation for a given molecular structure, which is not inherently guaranteed by the basic SMILES algorithm. We refer to a set of (atom) orders with canonical properties as canonical orders (McKay et al., 1981; McKay & Piperno, 2014). The canonicalization of SMILES involves a deterministic process where the algorithm selects a unique starting atom and follows a set of predefined rules to traverse the molecule in a systematic way. This results in a consistent and reproducible ordering of atoms and bonds within the SMILES string, irrespective of the initial input format. The canonical form is crucial for database searches and for ensuring consistency in chemical databases, as it prevents duplicates and allows for efficient indexing and retrieval of molecular data, which ensures maximum invariance for atom reordering.

To formally study which molecules the canonical forms can distinguish between and not, we first give the below definition following graph theories.

Definition 3.1. [3D Molecular Graph Isomorphism] Let $\mathcal{M}_1 = (V_1, Z_1)$ and $\mathcal{M}_2 = (V_2, Z_2)$ be two 3D molecular graphs, where z_i is the node type vector and v_i is the node coordinates of the molecule \mathcal{M}_i . Let $ver(\cdot)$ denote the set of vertices, $attr(\cdot)$ denote node attributes, and no edge exists. Let $\mathcal{M}_1 \cong \mathcal{M}_2$ denote two attributed graphs are isomorphic. Two 3D molecules \mathcal{M}_1 and \mathcal{M}_2 are 3D isomorphic, denoted as $\mathcal{M}_1 \cong_{3D} \mathcal{M}_2$, if there exists a bijection $b: ver(\mathcal{M}_1) \to ver(\mathcal{M}_2)$ such that for every atom in \mathcal{M}_1 indexed i, $z_i^{\mathcal{M}_1} = z_{b(i)}^{\mathcal{M}_2}$, and there exists a 3D transformation $\tau \in SE(3)$ such that $v_i^{\mathcal{M}_1} = \tau(v_{b(i)}^{\mathcal{M}_2})$. If a small error ϵ is allowed such that $|v_i^{\mathcal{M}_1} - \tau(v_{b(i)}^{\mathcal{M}_2})| \le \epsilon$, we call the two 3D graphs ϵ -constrained 3D isomorphic.

This leads us to the following guarantee.

Lemma 3.2. [Canonical Ordering for 3D Molecular Graph Isomorphism] Let $\mathcal{M}_1 = (V_1, Z_1)$ and $\mathcal{M}_2 = (V_2, Z_2)$ be two 3D molecular graphs following Def. 3.1. Let $L : \mathcal{M} \to \mathcal{L}$ be a function that maps a molecule $\mathcal{M} \in \mathcal{M}$, the set of all finite 3D molecular graphs, to its canonical order $L(\mathcal{M}) \in \mathcal{L}$, the set of all possible canonical orders, as produced by the canonical SMILES. Then the following equivalence holds:

$$L(\mathcal{M}_1) = L(\mathcal{M}_2) \Leftrightarrow \mathcal{M}_1 \cong_{3D} \mathcal{M}_2$$

where $\mathcal{M}_1 \cong_{3D} \mathcal{M}_2$ denotes that \mathcal{M}_1 and \mathcal{M}_2 are 3D isomorphic.

Lemma 3.2 indicates that the established ordering with canonical SMILES is both complete (sufficient to distinguish non-3D-isomorphic molecules) and sound (not distinguishing actually 3D-isomorphic molecules). Detailed proof is provided in Appendix C.1.

3.3.2 SE(3)-Equivariant Molecule and Fragment Frames Construction

To integrate 3D structure information into our sequences, one main challenge is to ensure the SE(3)-invariance property. Specifically, given a 3D molecule, if it is rotated or translated in the 3D space, its 3D representation should be unchanged. In order to incorporate invariance, we first need to construct SE(3)-equivariant frames for fragments and whole molecules.

Given a 3D molecule \mathcal{M} with atom types Z and atom coordinates V, we first build a **molecule local** coordinate frame $\mathbf{m} = (x, y, z)$ based on the input molecule. For the fragments $\{\mathcal{G}_i\}_{i=1}^k$ of \mathcal{M} , we sort the k fragments based on the canonical order $L(\mathcal{M})$, specifically by the order of a fragment's first-ranked atom. We calculate the average atom coordinates as the center of each fragment. As shown in Figure 2, the frame is built based on the first three non-collinear fragment centers in the canonical order. Let ℓ_1, ℓ_2 , and ℓ_m be the indices of these three fragment centers. Then the molecule local frame $\mathbf{m} = (x, y, z)$ is calculated as

$$x = \text{normalize}(v_{\ell_2} - v_{\ell_1}), \quad y = \text{normalize}((v_{\ell_m} - v_{\ell_1}) \times x), \quad z = x \times y,$$
 (1)

where $normalize(\cdot)$ is the function to normalize a vector to unit length. Note that the molecule local frame is equivariant to the rotation and translation of the input molecule.

Given the basis vectors (x, y, z) of the molecule local frame, we can construct the transformation between the molecule local frame m and the world frame w, which we denote as $m \to w$. Specifically, the transformation involves a rotation matrix $R_{m\to w} \in \mathbb{R}^{3\times 3}$ with $|R_{m\to w}|=1$ and a translation vector $t_{m\to w} \in \mathbb{R}^3$. Since the basis vectors (x,y,z) are already normalized and orthogonal to each other, we can directly stack them together to form the rotation matrix, such that $R_{m\to w}=[x^T,y^T,z^T]$. For the translation vector, we can set $t_{m\to w}=v_{\ell_1}$ as it represents the displacement between the origins of the two frames.

Next, we need to build the local coordinate system for each 3D fragment. Similar to the building process of the molecule local frame, we use the first three non-collinear atoms in a fragment to construct the **fragment local coordinate frame** and we denote it as \mathfrak{g} . The fragment local frame is also equivariant to the rotation and translation of the input molecule. Similarly, we can obtain the rotation matrix $R_{\mathfrak{g}\to\mathfrak{w}}$ and translation vector $\boldsymbol{t}_{\mathfrak{g}\to\mathfrak{w}}$, which represent the orientation and displacement between the fragment local frame and the world frame, respectively.

Under the fragment local frame, we can obtain the local coordinates of atoms $V_{\mathcal{G}_i} \in \mathbb{R}^{q \times 3}$ in the *i*-th fragment, where q denotes the number of atoms in a fragment. Then, we save each splitted fragment from the training set into a dictionary with the key to be the canonical SMILES of each fragment and the value to be the atom types and atom local coordinates in each fragment under the associated fragment local frame.

With the transformation from the world frame to the molecule local frame and from the world frame to the fragment local frame, we can derive the transformation between the molecule local frame and the fragment local frame by using homogeneous transformation conversion. Specifically, we construct homogeneous transformation matrices from rotation matrices R and translation vectors t. Formally, we have

$$T_{\mathbf{m}\to\mathbf{w}} = \begin{bmatrix} R_{\mathbf{m}\to\mathbf{w}} & \mathbf{t}_{\mathbf{m}\to\mathbf{w}} \\ \mathbf{0} & 1 \end{bmatrix}, \ T_{\mathbf{g}\to\mathbf{w}} = \begin{bmatrix} R_{\mathbf{g}\to\mathbf{w}} & \mathbf{t}_{\mathbf{g}\to\mathbf{w}} \\ \mathbf{0} & 1 \end{bmatrix}, \tag{2}$$

where $T \in \mathbb{R}^{4 \times 4}$ denotes the homogeneous transformation matrix and $\mathbf{0} \in \mathbb{R}^{3 \times 1}$ is a zero vector.

Then, we can use the chain rule of coordinate frame transformations to obtain the homogeneous transformation between molecule and fragment local frames. Formally,

$$T_{g\to m} = T_{m\to w}^{-1} T_{g\to w} = \begin{bmatrix} R_{m\to w}^T & -R_{m\to w}^T \boldsymbol{t}_{m\to w} \\ \boldsymbol{0} & 1 \end{bmatrix} \begin{bmatrix} R_{g\to w} & \boldsymbol{t}_{g\to w} \\ \boldsymbol{0} & 1 \end{bmatrix}$$
$$= \begin{bmatrix} R_{m\to w}^T R_{g\to w} & R_{m\to w}^T (\boldsymbol{t}_{g\to w} - \boldsymbol{t}_{m\to w}) \\ \boldsymbol{0} & 1 \end{bmatrix}. \tag{3}$$

From the homogeneous transformation matrix $T_{\mathfrak{g}\to\mathfrak{m}}$, we can extract the rotation matrix $R_{\mathfrak{g}\to\mathfrak{m}}$ which will be used to obtain invariant representations as described in Section 3.3.3 and the translation vector $t_{\mathfrak{g}\to\mathfrak{m}}$ such that

$$R_{\mathfrak{g}\to\mathfrak{m}} = R_{\mathfrak{m}\to\mathfrak{w}}^T R_{\mathfrak{g}\to\mathfrak{w}}, \quad t_{\mathfrak{g}\to\mathfrak{m}} = R_{\mathfrak{m}\to\mathfrak{w}}^T (t_{\mathfrak{g}\to\mathfrak{w}} - t_{\mathfrak{m}\to\mathfrak{w}}).$$
 (4)

Figure 3: Illustraions of equivariant local frames. Left: If the molecule is translated and rotated, the molecule and fragment local frames are transformed accordingly. Right: Local frames are constructed using the first three non-collinear points, and the spherical coordinates are obtained under the local frame. More details are shown in Section 3.3.2 and Section 3.3.3.

For each fragment in the fragment dictionary, apart from atom types and atom local coordinates, we also need to save the displacement $t_{\mathfrak{g}\to c(\mathcal{G})}$ between the origin of the fragment local frame and the fragment center, which can be calculated via

$$t_{\mathfrak{g}\to c(\mathcal{G})} = V_{c(\mathcal{G})}^{\mathfrak{m}} - t_{\mathfrak{g}\to\mathfrak{m}},$$
 (5)

where $c(\mathcal{G})$ denotes the center of any fragment \mathcal{G} , and $V_{c(\mathcal{G})}^{\mathfrak{m}}$ represents the coordinates of the fragment center under the molecule local frame. $t_{\mathfrak{q} \to c(\mathcal{G})}$ will be used when converting atom local coordinates from fragment local frame back to the world frame, which is described in Section 3.3.3.

3.3.3 SE(3)-Invariant Fragment Local Representations

After establishing the frames, we use a function $f(\cdot)$ to convert the coordinates of each fragment center to **spherical coordinates** d, θ, ϕ under the molecule frame $\mathfrak{m} = (\boldsymbol{x}, \boldsymbol{y}, \boldsymbol{z})$. Specifically, for each fragment center ℓ_i with coordinate \boldsymbol{v}_{ℓ_i} , the corresponding spherical coordinate is

$$d_{\ell_i} = ||\boldsymbol{v}_{\ell_i} - \boldsymbol{v}_{\ell_1}||_2, \quad \theta_{\ell_i} = \arccos\left((\boldsymbol{v}_{\ell_i} - \boldsymbol{v}_{\ell_1}) \cdot \boldsymbol{z}/d_{\ell_i}\right),$$

$$\phi_{\ell_i} = \operatorname{atan2}\left((\boldsymbol{v}_{\ell_i} - \boldsymbol{v}_{\ell_1}) \cdot \boldsymbol{y}, (\boldsymbol{v}_{\ell_i} - \boldsymbol{v}_{\ell_1}) \cdot \boldsymbol{x}\right).$$
(6)

The spherical coordinates show the relative position of each fragment under the molecule frame m. As shown in Figure 3, if the molecular coordinates are rotated by a matrix R and translated by a vector t, the transformed spherical coordinates remain the same, so the spherical coordinates are SE(3)-invariant.

Compared to Cartesian coordinates, spherical coordinate values are bounded in a smaller region, namely, a range of $[0,\pi]/[0,2\pi]$. Given the same numerical constraints, spherical coordinates require a smaller vocabulary size, and given the same vocabulary size, spherical coordinates present less information loss. This makes spherical coordinates advantageous in discretized representations and thus easier to be modeled by LMs. Experiments also show the superiority of invariant spherical coordinates over invariant Cartesian coordinates, as detailed in Appendix A.4

Apart from the spherical coordinates of the fragment center point under the molecule local frame, we also need the orientation of the fragment local frame with respect to the molecule local frame. One option is to directly use the rotation matrix $R_{\rm g \to m}$ we derived above. However, the rotation matrix representation has redundant information since 3D rotation in Euclidean space only has three degrees of freedom, and it can also unnecessarily increase the context length for LMs. To have a more compact rotation representation, we use a function $g(\cdot,\cdot)$ that takes in both the molecule and fragment local frames to obtain a rotation vector, which indicates the rotation axis and angle. Specifically, we first calculate the rotation matrix $R_{\rm g \to m}$ in $g(\cdot,\cdot)$, as described in Section 3.3.2, then we can obtain the rotation angle ψ and rotation axis $a=(a_x,a_y,a_z)$ from the rotation matrix. Next, we can calculate **rotation vector** $m=(m_x,m_y,m_z)$ via $m=\psi a$. Detailed derivation of ψ and a can be found in Appendix B.

Conversely, given the spherical coordinates of the fragment centers under the molecule local frame and the rotation vector \boldsymbol{m} between the fragment and molecule local frames, we can derive the atom coordinates in the world frame. Specifically, we first convert spherical coordinates to Cartesian coordinates $V_{c(\mathcal{G})}^{\mathrm{m}}$ and transform the rotation vector back to the rotation matrix $R_{\mathrm{g}\to\mathrm{m}}$. Then, we can

use coordinate transformation to convert atom coordinates from the fragment local frame to the world frame. Formally,

$$\boldsymbol{t}_{\mathfrak{g}\to\mathfrak{m}} = V_{c(\mathcal{G})}^{\mathfrak{m}} - \boldsymbol{t}_{\mathfrak{g}\to c(\mathcal{G})}, \quad V^{\mathfrak{m}} = V^{\mathfrak{g}} R_{\mathfrak{g}\to\mathfrak{m}}^T + \boldsymbol{t}_{\mathfrak{g}\to\mathfrak{m}}, \quad V^{\mathfrak{w}} = V^{\mathfrak{m}} R_{\mathfrak{m}\to\mathfrak{w}}^T + \boldsymbol{t}_{\mathfrak{m}\to\mathfrak{w}}. \tag{7}$$

where $V^{(\cdot)}$ denotes atom coordinates under a certain coordinate frame and $t_{\mathfrak{g}\to c(\mathcal{G})}$ can be retrieved from the fragment dictionary built in Section 3.3.2. As for $R_{\mathfrak{m}\to\mathfrak{w}}$ and $t_{\mathfrak{m}\to\mathfrak{w}}$, they are associated with the reference molecule for a given protein pocket when we construct the molecule local frame, and we can still use them when we generate new molecules for the same protein pocket.

Formally, with the SE(3)-equivariant local frames constructed in Section 3.3.2, we have the following properties of local representations built in this section.

Lemma 3.3. Let $\mathcal{M}=(V,Z)$ be a 3D molecular graph with node type matrix Z and node coordinate matrix V. Let \mathfrak{m} be equivariant local frames of \mathcal{M} built based on the first three non-collinear fragment centers in $\mathbf{L}(\mathcal{M})$ and \mathfrak{g} be equivariant local frames of any fragment \mathcal{G}_i built based on the first three non-collinear atoms in $\mathbf{L}(\mathcal{G}_i)$. $f(\cdot)$ is our function that maps 3D coordinate matrix V of \mathcal{M} to spherical representations S under the molecule local frame \mathfrak{m} . $g(\cdot,\cdot)$ is the function that maps the molecule local frame \mathfrak{m} and fragment local frame \mathfrak{g} to rotation vectors m. Then for any 3D transformation $\tau \in SE(3)$, we have $f(V) = f(\tau(V))$ and $g(\mathfrak{m},\mathfrak{g}) = g(\tau(\mathfrak{m},\mathfrak{g}))$. Given spherical representations S = f(V) and rotation vectors $m = g(\mathfrak{m},\mathfrak{g})$, there exist a transformation $\tau \in SE(3)$, such that $f^{-1}(S) = \tau(V)$ and $g^{-1}(m) = \tau(\mathfrak{m},\mathfrak{g})$.

Lemma 3.3 shows that our spherical and rotation vector representations are SE(3)-invariant, and we can reconstruct original molecules from those representations, differing only by a SE(3) transformation. Detailed proof is provided in Appendix C.2.

3.3.4 Frag2Seq: Fragment and Geometry Aware Tokenization

With ordering that reduces molecule structures to 1D sequences and SE(3)-invariant spherical and rotation representations, both ensuring minimum 3D information loss, we develop a reversible transformation from 3D molecular fragments to 1D sequences. Figure 2 shows an overview of our method, which we term as Frag2Seq. Specifically, given a molecule $\mathcal M$ with k fragments, we concatenate the fragment-position vector $[s_i,d_i,\theta_i,\phi_i,m_{xi},m_{yi},m_{zi}]$ of every fragment $\mathcal G_i$ in $\mathcal M$ into a 1D sequence by its canonical order, ℓ_1,\cdots,ℓ_k , where s_i is the canonical SMILES string of $\mathcal G_i$. To define the properties of Frag2Seq, we formulate Frag2Seq and our major theoretical derivations below.

Theorem 3.4. [Bijective Mapping] Following Def. 3.1, let $\mathcal{M}_1 = (V_1, Z_1)$ and $\mathcal{M}_2 = (V_2, Z_2)$ be two 3D molecular graphs. Let $\mathbf{L}(\mathcal{M})$ be the canonical order for \mathcal{M} and $f(\cdot)$ and $g(\cdot, \cdot)$ be the functions following Lemma 3.3. Let the fragment-position vector for a molecule fragment \mathcal{G}_i be $\mathbf{x}_i^* = [s_i, d_i, \theta_i, \phi_i, m_{xi}, m_{yi}, m_{zi}]$, where the vector elements are derived from $f(\cdot)$ and $g(\cdot, \cdot)$ as predefined. For the fragments $\{\mathcal{G}_i\}_{i=1}^k$ of \mathcal{M} , we construct canonical order $\mathbf{L}(\mathcal{M})$ for the k fragments, ℓ_1, \cdots, ℓ_k , specifically by the order of a fragment's first-ranked atom. We define Frag2Seq: $\mathcal{M} \to \mathcal{U}$, which maps a molecule $\mathcal{M} \in \mathcal{M}$ to its sequence representation $U \in \mathcal{U}$, the set of all possible sequence representations, as

$$Frag2Seq(\mathcal{M}) = concat(\boldsymbol{x}_{\ell_1}^*, \cdots, \boldsymbol{x}_{\ell_k}^*),$$

where $concat(\cdot)$ concatenates elements as a sequence. Then $Frag2Seq(\cdot)$ is a surjective function, and the following equivalence holds:

$$Frag2Seq(\mathcal{M}_1) = Frag2Seq(\mathcal{M}_2) \Leftrightarrow \mathcal{M}_1 \cong_{3D} \mathcal{M}_2,$$

where $\mathcal{M}_1 \cong_{3D} \mathcal{M}_2$ denotes \mathcal{M}_1 and \mathcal{M}_2 are 3D isomorphic. If we allow rounding up spherical coordinate and rotation vector values to $\geq b$ decimal places, then the surjectivity and equivalence still hold, only molecules \mathcal{M}_1 and \mathcal{M}_2 are $(|10^{-b}|/2)$ -constrained 3D isomorphic.

Theorem 3.4 establishes guarantees that we can uniquely construct a 1D sequence given a 3D molecule using Frag2Seq, and uniquely reconstruct a 3D molecule given a sequence output of Frag2Seq. Furthermore, two sequence outputs from Frag2Seq are identical if and only if the two corresponding molecules are 3D isomorphic. This enables sequential tokenization of 3D molecules while preserving structural completeness and geometric invariance. Due to the necessity of discreteness in tokenization




Figure 4: Visualization of our generated 3D molecules that have higher binding affinity than the reference molecule in the test set. A higher QED indicates more drug-likeness, and a lower Vina score indicates higher binding affinity.

for LMs, in reality, numerical values need to be discretized before concatenation. In practice, we round up numerical values to certain decimal places. In this case, Theorem 3.4 also extends guarantees for the practical use of Frag2Seq. If we allow a round-up error below $|10^{-b}|/2$ for coordinates when distinguishing 3D isomorphism, all properties still hold. This implies that the practical Frag2Seq implementation retains near-complete geometric information and invariance, with numerical precision of $\epsilon \leq |10^{-b}|/2$.

With discreteness incorporated, we can collect a finite vocabulary covering all accessible fragment samples to enable tokenization for LMs. Specifically, we use vocabularies consisting of fragment type tokens such as $O, O = C, c1ccccc1, \cdots$, and numerical tokens such as $-8.126, 0.05^{\circ}$ or -1.702^{*} . The numerical tokens range from the smallest to the largest distance, angle, and rotation values with restricted precision of 2 or 3 decimal places.

3.4 CONDITIONAL TRAINING AND GENERATION

After we obtain the sequence representation of 3D molecules $U = \{u_1, \cdots, u_n\}$, we need to model the distribution of such 3D geometry-aware sequences. We adopt GPT (Radford et al., 2018) as the base model to learn the distribution. To incorporate the protein pocket condition, we use pre-trained inverse folding model ESM-IF1 (Hsu et al., 2022) to obtain node embeddings of the protein backbone. Then, we add cross-attention between protein node embeddings and ligand token embeddings after the multi-head self-attention in each attention block, in which queries are from ligand token embedding and keys and values are from protein node embedding. For training, we use the standard next-token prediction cross-entropy loss to maximize the following likelihood:

$$\mathcal{L}(U;\mathcal{P}) = \sum_{i} \log p_{\theta}(u_i|u_{i-1},\cdots,u_1;\mathcal{P}). \tag{8}$$

To generate molecules conditioned on a protein pocket, we first need to sample initial fragment tokens from the first-token distribution in the training set. Then, we can generate the following tokens autoregressively by sampling from the conditional distribution $p_{\theta}(u_i|u_{i-1},\cdots,u_1;\mathcal{P})$ and we stop the generation when the maximum length is reached or the ending token is sampled.

4 EXPERIMENTS

We empirically show the effectiveness of our method in generating ligands for protein pockets. In Section 4.1, we describe the experimental setup, including dataset, baselines, and evaluation metrics. Then, in Section 4.2, we present our results about binding affinity, chemical properties, and efficiency. In Section 4.3, we show more results about structural analysis. Due to the limited space, we conduct ablation studies on several design choices in Appendix A.4, and more results about efficiency in Appendix A.5.

4.1 SETUP

Dataset. Following Schneuing et al. (2022), we use the CrossDocked dataset (Francoeur et al., 2020) that is further curated by previous work (Luo et al., 2021). More details about the dataset is provided in Appendix A.1.

Table 1: Summary of molecular properties for generated molecules by our method and other baselines. * denotes the property results taken from the DiffSBDD paper. † denotes that we re-evaluate the properties of generated molecules of those baselines using the DiffSBDD evaluation code for a fair comparison. The best results are annotated in bold.

Methods	Vina Score (↓)	High Affinity (↑)	QED (†)	SA (†)	Lipinski (†)	Diversity (†)	Time (s, \downarrow)
Test set	-6.871 ± 2.32	-	0.476 ± 0.20	0.728 ± 0.14	4.340 ± 1.14	-	-
3D-SBDD*	-5.888 ± 1.91	0.364 ± 0.31	0.502 ± 0.17	0.675 ± 0.14	4.787 ± 0.51	0.742 ± 0.09	15986.4 ± 9851.0
Pocket2Mol*	-7.058 ± 2.80	0.515 ± 0.31	0.572 ± 0.16	$\boldsymbol{0.752 \pm 0.12}$	4.936 ± 0.27	0.735 ± 0.15	2827.3 ± 1456.8
GraphBP*	-4.719 ± 4.03	0.183 ± 0.21	0.502 ± 0.12	0.307 ± 0.09	4.883 ± 0.37	$\boldsymbol{0.844 \pm 0.01}$	1162.8 ± 438.5
TargetDiff*	-7.318 ± 2.47	0.581 ± 0.31	0.483 ± 0.20	0.584 ± 0.13	4.594 ± 0.83	0.718 ± 0.09	~ 3428
DecompDiff†	-6.607 ± 2.11	0.423 ± 0.25	0.496 ± 0.21	0.659 ± 0.14	4.493 ± 1.02	0.722 ± 0.10	~ 6189
DiffSBDD*	-7.177 ± 3.28	0.499 ± 0.30	0.556 ± 0.20	0.729 ± 0.12	4.742 ± 0.59	0.718 ± 0.07	629.9 ± 277.2
FLAG†	-6.389 ± 3.24	0.478 ± 0.34	0.487 ± 0.19	0.702 ± 0.15	4.656 ± 0.74	0.701 ± 0.14	1289.1 ± 378.0
DrugGPS†	-6.608 ± 2.38	0.421 ± 0.24	0.467 ± 0.21	0.628 ± 0.15	4.495 ± 0.99	0.738 ± 0.10	1007.8 ± 554.1
Lingo3DMol†	-7.257 ± 1.69	0.625 ± 0.36	0.269 ± 0.15	0.656 ± 0.08	3.121 ± 1.25	0.480 ± 0.12	1481.9 ± 1512.8
Frag2Seq	-7.366 ± 1.96	$\boldsymbol{0.653 \pm 0.33}$	0.645 ± 0.15	0.642 ± 0.11	4.989 ± 0.11	0.711 ± 0.07	48.8 ± 14.6

Baselines. We compare with recent state-of-the-art methods in structure-based drug design. 3D-SBDD (Luo et al., 2021), Pocket2Mol (Peng et al., 2022), and GraphBP (Liu et al., 2022) generate atoms in an autoregressive scheme. TargetDiff (Guan et al., 2022), DecompDiff (Guan et al., 2023), and DiffSBDD (Schneuing et al., 2022) are diffusion-based methods that generate all atoms in one shot. FLAG (Zhang et al., 2022) and DrugGPS (Zhang & Liu, 2023) generate molecules motif-bymotif. Lingo3DMol (Feng et al., 2024) uses a language model to generate fragment-based SMILES and then predict coordinates. The language model is pre-trained on 12 million 3D molecules using a denoising strategy.

Evaluation Metrics. We adopt commonly-used metrics used in previous work (Schneuing et al., 2022; Peng et al., 2022) to evaluate the quality of our generated molecules: (1) **Vina Score** estimates the binding affinity between generated molecules and given protein pockets; (2) **High Affinity** measures the percentage of generated molecules that have higher binding affinity than the reference molecule for a certain protein; (3) **QED** is a measure used to assess the drug-likeness of a molecule based on its molecular properties; (4) **SA** estimates how easy it would be to synthesize a given chemical compound; (5) **Lipinski** measures how well a molecule satisfies the Lipinski's rule of five (Lipinski et al., 2012), which evaluates the drug-likeness of a molecule; (6) **Diversity** measures the average pairwise diversity (calculated as 1 - Tanimoto similarity) of generated molecules for a binding pocket; (7) **Time** is the average time cost to generate 100 molecules for a protein pocket in the test set. All the Vina scores are calculated by QVina (Alhossary et al., 2015), and the chemical properties are calculated by RDKit (Bento et al., 2020).

4.2 RESULTS

We show the results of the above metrics for our method and baselines in Table 1. The results show that our method can achieve better or competitive performance with other baseline methods. Specifically, our method achieves the best result on QED and Lipinski, which indicates that our generated molecules possess better drug characteristics. Additionally, our method obtains the best Vina score and high affinity met-




Figure 5: Comparison of the distribution of carbon-carbon bond distance. Jensen-Shannon divergence (JSD) between reference molecules and generated molecules is reported.

ric, which shows that our model captures more accurate interactions between ligands and protein pockets to improve the binding affinity. Moreover, our method has much better sampling efficiency than the baselines due to our simple generation pipeline and fragment-based generation strategy.

In Figure 4, we provide several examples of our generated 3D molecules for a certain protein pocket (PDB id 4m7t). The reference molecule is provided in the test set, and our generated molecules

exhibit higher binding affinity than the reference molecule. These examples can validate that our method has the capability to capture the complex interaction between proteins and ligands in order to generate novel molecules that have higher binding affinity while retaining similar or even better drug-likeness properties than the reference molecule.

4.3 STRUCTURAL ANALYSIS

In Figure 5, we plot the empirical distribution of carbon-carbon bond distances of generated molecules and reference molecules. The reference distribution (gray) has two modes, but most methods can only capture one mode due to mode collapse. Even though TargetDiff exhibits two modes in the distribution, it still suffers from the over-smoothness issue. Comparatively, our method can better capture those two modes in the reference distribution. Furthermore, we calculate Jensen-Shannon divergence (JSD) (Lin, 1991) between the bond distance distribution of reference and generated molecules for each method to quantitatively evaluate the distribution fitting capability. We can observe that our method outperforms other methods by a clear margin.

To further evaluate the structures of generated molecules, we calculate the Kullback-Leibler (KL) divergence of bond angles and dihedral angles between generated molecules and reference molecules in the test set. The results in Table 2 show that our method achieves better KL divergence than other representative baselines in most cases, which demonstrates that Frag2Seq can well capture the structural distribution of the data and generate more valid substructures.

Table 2: The KL divergence of the distribution of the bond and dihedral angles between generated molecules and reference molecules. The lower letters indicate the atoms in the aromatic rings. * denotes numbers taken from the original paper due to the absence of those dihedral angles in regenerated structures.

Angles	liGAN	3D-SBDD	Pocket2Mol	TargetDiff	FLAG	Frag2Seq
CCC CCO NCC	1.266 1.475 1.312	$0.465 \\ 0.618 \\ 0.619$	0.770 1.104 0.754	$0.507 \\ 0.713 \\ 0.585$	0.497 0.768 0.427	0.263 0.306 0.578
CCCC cccc CCCO Cccc CC=CC	0.197 0.786 0.206 0.725 0.526	0.250 1.044 0.263 0.939 0.655	0.215 4.49^* 0.245 2.85^* 0.296	0.170 0.229 0.191 0.397 0.301	0.164 0.516 0.180 0.311 0.345	0.113 0.041 0.198 0.109 0.133

5 CONCLUSIONS, BROADER IMPACTS, AND LIMITATIONS

In this work, we develop a method to convert molecules into fragment-based SE(3)-invariant sequences which can be naturally processed by language models. We use a protein inverse folding model to obtain protein embeddings and integrate them into the language model via cross-attention. Our experiments show the great potential of using language models in structure-based drug design, which can potentially accelerate drug discovery by enhancing the efficiency and accuracy of identifying viable drug candidates. However, our method also has limitations. The chemical bonds are not directly generated by the language model and need to be inferred by OpenBabel (O'Boyle et al., 2011), and real number tokenization requires quantization, leading to some accuracy loss.

REPRODUCIBILITY STATEMENT

To ensure the reproducibility of this work, for our theoretical results, all assumptions and proofs are included in Appendix C. For the experiments, we provide full details including all dataset accessibility, training setup, architecture, and hyper-parameters in Appendix A. The finalized code will be released upon acceptance.

REFERENCES

- Josh Achiam, Steven Adler, Sandhini Agarwal, Lama Ahmad, Ilge Akkaya, Florencia Leoni Aleman, Diogo Almeida, Janko Altenschmidt, Sam Altman, Shyamal Anadkat, et al. GPT-4 technical report. arXiv preprint arXiv:2303.08774, 2023.
- Amr Alhossary, Stephanus Daniel Handoko, Yuguang Mu, and Chee-Keong Kwoh. Fast, accurate, and reliable molecular docking with quickvina 2. *Bioinformatics*, 31(13):2214–2216, 2015.
- Amy C Anderson. The process of structure-based drug design. *Chemistry & biology*, 10(9):787–797, 2003.
 - Viraj Bagal, Rishal Aggarwal, PK Vinod, and U Deva Priyakumar. MolGPT: molecular generation using a transformer-decoder model. *Journal of Chemical Information and Modeling*, 62(9): 2064–2076, 2021.
 - Jürgen Bajorath. Chemical language models for molecular design. *Molecular Informatics*, 43(1): e202300288, 2024.
 - A Patrícia Bento, Anne Hersey, Eloy Félix, Greg Landrum, Anna Gaulton, Francis Atkinson, Louisa J Bellis, Marleen De Veij, and Andrew R Leach. An open source chemical structure curation pipeline using rdkit. *Journal of Cheminformatics*, 12:1–16, 2020.
 - Andrew E Blanchard, Debsindhu Bhowmik, Zachary Fox, John Gounley, Jens Glaser, Belinda S Akpa, and Stephan Irle. Adaptive language model training for molecular design. *Journal of Cheminformatics*, 15(1):1–12, 2023.
 - Andres M Bran and Philippe Schwaller. Transformers and large language models for chemistry and drug discovery. *arXiv preprint arXiv:2310.06083*, 2023.
 - Tom Brown, Benjamin Mann, Nick Ryder, Melanie Subbiah, Jared D Kaplan, Prafulla Dhariwal, Arvind Neelakantan, Pranav Shyam, Girish Sastry, Amanda Askell, et al. Language models are few-shot learners. *Advances in neural information processing systems*, 33:1877–1901, 2020.
 - He Cao, Zijing Liu, Xingyu Lu, Yuan Yao, and Yu Li. InstructMol: Multi-modal integration for building a versatile and reliable molecular assistant in drug discovery. *arXiv preprint arXiv:2311.16208*, 2023.
 - Yangyang Chen, Zixu Wang, Xiangxiang Zeng, Yayang Li, Pengyong Li, Xiucai Ye, and Tetsuya Sakurai. Molecular language models: Rnns or transformer? *Briefings in Functional Genomics*, pp. elad012, 2023a.
 - Yuhan Chen, Nuwa Xi, Yanrui Du, Haochun Wang, Chen Jianyu, Sendong Zhao, and Bing Qin. From artificially real to real: Leveraging pseudo data from large language models for low-resource molecule discovery. *arXiv preprint arXiv:2309.05203*, 2023b.
 - Aakanksha Chowdhery, Sharan Narang, Jacob Devlin, Maarten Bosma, Gaurav Mishra, Adam Roberts, Paul Barham, Hyung Won Chung, Charles Sutton, Sebastian Gehrmann, et al. PaLM: Scaling language modeling with pathways. *Journal of Machine Learning Research*, 24(240):1–113, 2023.
 - Jacob Devlin, Ming-Wei Chang, Kenton Lee, and Kristina Toutanova. Bert: Pre-training of deep bidirectional transformers for language understanding. *arXiv preprint arXiv:1810.04805*, 2018.
 - Carl Edwards, Tuan Lai, Kevin Ros, Garrett Honke, Kyunghyun Cho, and Heng Ji. Translation between molecules and natural language. *arXiv preprint arXiv:2204.11817*, 2022.
 - Yin Fang, Ningyu Zhang, Zhuo Chen, Xiaohui Fan, and Huajun Chen. Molecular language model as multi-task generator. *arXiv preprint arXiv:2301.11259*, 2023.
 - Wei Feng, Lvwei Wang, Zaiyun Lin, Yanhao Zhu, Han Wang, Jianqiang Dong, Rong Bai, Huting Wang, Jielong Zhou, Wei Peng, et al. Generation of 3d molecules in pockets via a language model. *Nature Machine Intelligence*, pp. 1–12, 2024.

- Paul G Francoeur, Tomohide Masuda, Jocelyn Sunseri, Andrew Jia, Richard B Iovanisci, Ian Snyder, and David R Koes. Three-dimensional convolutional neural networks and a cross-docked data set for structure-based drug design. *Journal of chemical information and modeling*, 60(9):4200–4215, 2020.
 - Nathan C Frey, Ryan Soklaski, Simon Axelrod, Siddharth Samsi, Rafael Gomez-Bombarelli, Connor W Coley, and Vijay Gadepally. Neural scaling of deep chemical models. *Nature Machine Intelligence*, 5(11):1297–1305, 2023.
 - Albert Gu, Karan Goel, and Christopher Ré. Efficiently modeling long sequences with structured state spaces. *arXiv* preprint arXiv:2111.00396, 2021.
 - Jiaqi Guan, Wesley Wei Qian, Xingang Peng, Yufeng Su, Jian Peng, and Jianzhu Ma. 3d equivariant diffusion for target-aware molecule generation and affinity prediction. In *The Eleventh International Conference on Learning Representations*, 2022.
 - Jiaqi Guan, Xiangxin Zhou, Yuwei Yang, Yu Bao, Jian Peng, Jianzhu Ma, Qiang Liu, Liang Wang, and Quanquan Gu. Decompdiff: Diffusion models with decomposed priors for structure-based drug design. *Proceedings of Machine Learning Research*, 202:11827–11846, 2023.
 - Suhail Haroon, CA Hafsath, and AS Jereesh. Generative pre-trained transformer (GPT) based model with relative attention for de novo drug design. *Computational Biology and Chemistry*, 106:107911, 2023.
 - Chloe Hsu, Robert Verkuil, Jason Liu, Zeming Lin, Brian Hie, Tom Sercu, Adam Lerer, and Alexander Rives. Learning inverse folding from millions of predicted structures. In *International conference on machine learning*, pp. 8946–8970. PMLR, 2022.
 - Adam Izdebski, Ewelina Weglarz-Tomczak, Ewa Szczurek, and Jakub M Tomczak. De novo drug design with joint transformers. *arXiv preprint arXiv:2310.02066*, 2023.
 - Nikita Janakarajan, Tim Erdmann, Sarath Swaminathan, Teodoro Laino, and Jannis Born. Language models in molecular discovery. *arXiv preprint arXiv:2309.16235*, 2023.
 - Bowen Jing, Stephan Eismann, Patricia Suriana, Raphael John Lamarre Townshend, and Ron Dror. Learning from protein structure with geometric vector perceptrons. In *International Conference on Learning Representations*, 2020.
 - Mario Krenn, Florian Häse, A Nigam, Pascal Friederich, and Alán Aspuru-Guzik. Selfies: a robust representation of semantically constrained graphs with an example application in chemistry. *arXiv* preprint arXiv:1905.13741, 1(3), 2019.
 - Gregory W Kyro, Anton Morgunov, Rafael I Brent, and Victor S Batista. Chemspaceal: An efficient active learning methodology applied to protein-specific molecular generation. *ArXiv*, 2023.
 - Jiatong Li, Yunqing Liu, Wenqi Fan, Xiao-Yong Wei, Hui Liu, Jiliang Tang, and Qing Li. Empowering molecule discovery for molecule-caption translation with large language models: A chatgpt perspective. *arXiv* preprint arXiv:2306.06615, 2023a.
 - Yuesen Li, Chengyi Gao, Xin Song, Xiangyu Wang, Yungang Xu, and Suxia Han. DrugGPT: A GPT-based strategy for designing potential ligands targeting specific proteins. *bioRxiv*, pp. 2023–06, 2023b.
 - Youwei Liang, Ruiyi Zhang, Li Zhang, and Pengtao Xie. DrugChat: towards enabling ChatGPT-like capabilities on drug molecule graphs. *arXiv* preprint arXiv:2309.03907, 2023.
 - Jianhua Lin. Divergence measures based on the shannon entropy. *IEEE Transactions on Information theory*, 37(1):145–151, 1991.
 - Christopher A Lipinski, Franco Lombardo, Beryl W Dominy, and Paul J Feeney. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. *Advanced drug delivery reviews*, 64:4–17, 2012.

- Meng Liu, Youzhi Luo, Limei Wang, Yaochen Xie, Hao Yuan, Shurui Gui, Haiyang Yu, Zhao Xu, Jingtun Zhang, Yi Liu, et al. Dig: A turnkey library for diving into graph deep learning research. *The Journal of Machine Learning Research*, 22(1):10873–10881, 2021.
 - Meng Liu, Youzhi Luo, Kanji Uchino, Koji Maruhashi, and Shuiwang Ji. Generating 3d molecules for target protein binding. In *International Conference on Machine Learning*, pp. 13912–13924. PMLR, 2022.
 - Shengchao Liu, Weili Nie, Chengpeng Wang, Jiarui Lu, Zhuoran Qiao, Ling Liu, Jian Tang, Chaowei Xiao, and Animashree Anandkumar. Multi-modal molecule structure–text model for text-based retrieval and editing. *Nature Machine Intelligence*, 5(12):1447–1457, 2023a.
 - Zequn Liu, Wei Zhang, Yingce Xia, Lijun Wu, Shufang Xie, Tao Qin, Ming Zhang, and Tie-Yan Liu. Molxpt: Wrapping molecules with text for generative pre-training. *arXiv preprint arXiv:2305.10688*, 2023b.
 - Ilya Loshchilov and Frank Hutter. Decoupled weight decay regularization. *arXiv preprint arXiv:1711.05101*, 2017.
 - Renqian Luo, Liai Sun, Yingce Xia, Tao Qin, Sheng Zhang, Hoifung Poon, and Tie-Yan Liu. BioGPT: generative pre-trained transformer for biomedical text generation and mining. *Briefings in Bioinformatics*, 23(6):bbac409, 2022.
 - Shitong Luo, Jiaqi Guan, Jianzhu Ma, and Jian Peng. A 3d generative model for structure-based drug design. *Advances in Neural Information Processing Systems*, 34:6229–6239, 2021.
 - Youzhi Luo and Shuiwang Ji. An autoregressive flow model for 3D molecular geometry generation from scratch. In *International Conference on Learning Representations*, 2022.
 - Paul D Lyne. Structure-based virtual screening: an overview. *Drug discovery today*, 7(20):1047–1055, 2002.
 - Jiashun Mao, Jianmin Wang, Amir Zeb, Kwang-Hwi Cho, Haiyan Jin, Jongwan Kim, Onju Lee, Yunyun Wang, and Kyoung Tai No. Deep molecular generative model based on variant transformer for antiviral drug design. *Available at SSRN 4345811*, 2023a.
 - Jiashun Mao, Jianmin Wang, Amir Zeb, Kwang-Hwi Cho, Haiyan Jin, Jongwan Kim, Onju Lee, Yunyun Wang, and Kyoung Tai No. Transformer-based molecular generative model for antiviral drug design. *Journal of Chemical Information and Modeling*, 2023b.
 - Eyal Mazuz, Guy Shtar, Bracha Shapira, and Lior Rokach. Molecule generation using transformers and policy gradient reinforcement learning. *Scientific Reports*, 13(1):8799, 2023.
 - Brendan D McKay and Adolfo Piperno. Practical graph isomorphism, ii. *Journal of symbolic computation*, 60:94–112, 2014.
 - Brendan D McKay et al. Practical graph isomorphism. 1981.
 - Noel M O'Boyle, Michael Banck, Craig A James, Chris Morley, Tim Vandermeersch, and Geoffrey R Hutchison. Open babel: An open chemical toolbox. *Journal of cheminformatics*, 3:1–14, 2011.
 - Noel M O'Boyle. Towards a universal smiles representation-a standard method to generate canonical smiles based on the inchi. *Journal of cheminformatics*, 4:1–14, 2012.
 - Adam Paszke, Sam Gross, Francisco Massa, Adam Lerer, James Bradbury, Gregory Chanan, Trevor Killeen, Zeming Lin, Natalia Gimelshein, Luca Antiga, et al. Pytorch: An imperative style, high-performance deep learning library. *Advances in neural information processing systems*, 32, 2019.
 - Qizhi Pei, Wei Zhang, Jinhua Zhu, Kehan Wu, Kaiyuan Gao, Lijun Wu, Yingce Xia, and Rui Yan. Biot5: Enriching cross-modal integration in biology with chemical knowledge and natural language associations. *arXiv preprint arXiv:2310.07276*, 2023.

- Xingang Peng, Shitong Luo, Jiaqi Guan, Qi Xie, Jian Peng, and Jianzhu Ma. Pocket2mol: Efficient molecular sampling based on 3d protein pockets. In *International Conference on Machine Learning*, pp. 17644–17655. PMLR, 2022.
 - Alec Radford, Karthik Narasimhan, Tim Salimans, Ilya Sutskever, et al. Improving language understanding by generative pre-training. 2018.
 - Matthew Ragoza, Tomohide Masuda, and David Ryan Koes. Generating 3d molecules conditional on receptor binding sites with deep generative models. *Chemical science*, 13(9):2701–2713, 2022.
 - Arne Schneuing, Yuanqi Du, Charles Harris, Arian Jamasb, Ilia Igashov, Weitao Du, Tom Blundell, Pietro Lió, Carla Gomes, Max Welling, et al. Structure-based drug design with equivariant diffusion models. *arXiv preprint arXiv:2210.13695*, 2022.
 - Brian K Shoichet. Virtual screening of chemical libraries. *Nature*, 432(7019):862–865, 2004.
 - Martin Steinegger and Johannes Söding. Mmseqs2 enables sensitive protein sequence searching for the analysis of massive data sets. *Nature biotechnology*, 35(11):1026–1028, 2017.
 - Hugo Touvron, Thibaut Lavril, Gautier Izacard, Xavier Martinet, Marie-Anne Lachaux, Timothée Lacroix, Baptiste Rozière, Naman Goyal, Eric Hambro, Faisal Azhar, et al. Llama: Open and efficient foundation language models. *arXiv preprint arXiv:2302.13971*, 2023.
 - Emma P Tysinger, Brajesh K Rai, and Anton V Sinitskiy. Can we quickly learn to "translate" bioactive molecules with transformer models? *Journal of Chemical Information and Modeling*, 63 (6):1734–1744, 2023.
 - Ashish Vaswani, Noam Shazeer, Niki Parmar, Jakob Uszkoreit, Llion Jones, Aidan N Gomez, Łukasz Kaiser, and Illia Polosukhin. Attention is all you need. *Advances in neural information processing systems*, 30, 2017.
 - Zifeng Wang, Zichen Wang, Balasubramaniam Srinivasan, Vassilis N Ioannidis, Huzefa Rangwala, and Rishita Anubhai. Biobridge: Bridging biomedical foundation models via knowledge graph. *arXiv preprint arXiv:2310.03320*, 2023.
 - David Weininger. SMILES, a chemical language and information system. 1. introduction to methodology and encoding rules. *Journal of chemical information and computer sciences*, 28(1):31–36, 1988.
 - David Weininger, Arthur Weininger, and Joseph L Weininger. Smiles. 2. algorithm for generation of unique smiles notation. *Journal of chemical information and computer sciences*, 29(2):97–101, 1989.
 - Juan-Ni Wu, Tong Wang, Yue Chen, Li-Juan Tang, Hai-Long Wu, and Ru-Qin Yu. Fragment-based t-smiles for de novo molecular generation. *arXiv preprint arXiv:2301.01829*, 2023.
 - Jun Xia, Yanqiao Zhu, Yuanqi Du, Y Liu, and SZ Li. A systematic survey of chemical pre-trained models. IJCAI, 2023.
 - Yingce Xia, Kehan Wu, Pan Deng, Renhe Liu, Yuan Zhang, Han Guo, Yumeng Cui, Qizhi Pei, Lijun Wu, Shufang Xie, et al. Target-aware molecule generation for drug design using a chemical language model. *bioRxiv*, pp. 2024–01, 2024.
 - Tong Xie, Yuwei Wan, Wei Huang, Zhenyu Yin, Yixuan Liu, Shaozhou Wang, Qingyuan Linghu, Chunyu Kit, Clara Grazian, Wenjie Zhang, et al. DARWIN series: Domain specific large language models for natural science. *arXiv* preprint arXiv:2308.13565, 2023.
 - Zhongyin Xu, Xiujuan Lei, Mei Ma, and Yi Pan. Molecular generation and optimization of molecular properties using a transformer model. *Big Data Mining and Analytics*, 7(1):142–155, 2023.
 - Yasuhiro Yoshikai, Tadahaya Mizuno, Shumpei Nemoto, and Hiroyuki Kusuhara. Difficulty in learning chirality for transformer fed with smiles. *arXiv preprint arXiv:2303.11593*, 2023.

Qiang Zhang, Keyang Ding, Tianwen Lyv, Xinda Wang, Qingyu Yin, Yiwen Zhang, Jing Yu, Yuhao Wang, Xiaotong Li, Zhuoyi Xiang, et al. Scientific large language models: A survey on biological & chemical domains. *arXiv preprint arXiv:2401.14656*, 2024.

Weitong Zhang, Xiaoyun Wang, Weili Nie, Joe Eaton, Brad Rees, and Quanquan Gu. MoleculeGPT: Instruction following large language models for molecular property prediction. In *NeurIPS 2023 Workshop on New Frontiers of AI for Drug Discovery and Development*, 2023a.

Xuan Zhang, Limei Wang, Jacob Helwig, Youzhi Luo, Cong Fu, Yaochen Xie, Meng Liu, Yuchao Lin, Zhao Xu, Keqiang Yan, Keir Adams, Maurice Weiler, Xiner Li, Tianfan Fu, Yucheng Wang, Haiyang Yu, YuQing Xie, Xiang Fu, Alex Strasser, Shenglong Xu, Yi Liu, Yuanqi Du, Alexandra Saxton, Hongyi Ling, Hannah Lawrence, Hannes Stärk, Shurui Gui, Carl Edwards, Nicholas Gao, Adriana Ladera, Tailin Wu, Elyssa F. Hofgard, Aria Mansouri Tehrani, Rui Wang, Ameya Daigavane, Montgomery Bohde, Jerry Kurtin, Qian Huang, Tuong Phung, Minkai Xu, Chaitanya K. Joshi, Simon V. Mathis, Kamyar Azizzadenesheli, Ada Fang, Alán Aspuru-Guzik, Erik Bekkers, Michael Bronstein, Marinka Zitnik, Anima Anandkumar, Stefano Ermon, Pietro Liò, Rose Yu, Stephan Günnemann, Jure Leskovec, Heng Ji, Jimeng Sun, Regina Barzilay, Tommi Jaakkola, Connor W. Coley, Xiaoning Qian, Xiaofeng Qian, Tess Smidt, and Shuiwang Ji. Artificial intelligence for science in quantum, atomistic, and continuum systems, 2023b.

Zaixi Zhang and Qi Liu. Learning subpocket prototypes for generalizable structure-based drug design. In *International Conference on Machine Learning*, pp. 41382–41398. PMLR, 2023.

Zaixi Zhang, Yaosen Min, Shuxin Zheng, and Qi Liu. Molecule generation for target protein binding with structural motifs. In *The Eleventh International Conference on Learning Representations*, 2022.

A EXPERIMENTAL DETAILS AND ADDITIONAL RESULTS

A.1 DATASET DETAILS

Following previous work in SBDD (Schneuing et al., 2022; Luo et al., 2021; Peng et al., 2022; Guan et al., 2022; 2023), we use the CrossDocked2020 dataset to train and test our model. The dataset was originally created by Francoeur et al. (2020). We adopt the version that is further filtered in the previous work (Luo et al., 2021). To increase the data quality, they filter out data points that have binding pose RMSD greater than 1Å. The data split is performed according to 30% sequence identity using MMseqs2 (Steinegger & Söding, 2017). Finally, there are 100000 protein-ligand training pairs and 100 proteins in the test set. The dataset curated by Luo et al. (2021) is publicly available at https://github.com/luost26/3D-Generative-SBDD/blob/main/data/README.md under the MIT license.

A.2 PROTEIN ENCODER DETAILS

We use the pre-trained ESM-IF1 model to obtain protein node embeddings. ESM-IF1 model is also known as GVP-Transformer that is developed by Hsu et al. (2022). It is an inverse folding model that is used to design protein amino acid sequences given 3D backbone structures. The ESM-IF1 model uses a modified Geometric Vector Perceptron (GVP) layers (Jing et al., 2020) to extract rotational and translational invariant features, followed by an autoregressive encoder-decoder Transformer (Vaswani et al., 2017). The model weights of ESM-IF1 are publicly available at https://github.com/facebookresearch/esm under the MIT license.

A.3 NETWORK AND TRAINING DETAILS

For the language model, we use the GPT-1 architecture (Radford et al., 2018) with 12 layers, 12 attention heads, and a hidden embedding size of 768. Cross-attention is added after self-attention in each layer. The protein embedding size generated by the ESM-IF1 model is 512 and is increased to 768 by an MLP layer before the protein embeddings are fed into the cross-attention. The architecture of the cross-attentions is the same as the self-attention, except that the key and value are from the protein embeddings. The initial learning rate is set as $4e^{-4}$, and the batch size is 64. We implement our methods using PyTorch (Paszke et al., 2019) and we adopt the AdamW optimizer (Loshchilov & Hutter, 2017) with $\beta_1 = 0.9$, $\beta_2 = 0.95$. We adopt linear warm up and cosine scheduler to adaptively adjust the learning rate. Specifically, during the first 10% of total training tokens, we increase the learning rate from 0 to the initial learning rate. Then, the learning rate decreases to $4e^{-5}$ by using a cosine decay scheduler. We use a single NVIDIA A100 GPU to train our model. We set the maximum context length as 512 for all the experiments except for the ablation study on converting proteins into sequences. In that case, the maximum context length is increased to 850 to accommodate the preappended protein sequences.

A.4 ABLATION STUDY

In this section, we conduct ablations studies on the 3D representation, fragmentation, and protein embedding in order to show how these factors affect the performance of the language model on the SBDD task.

First, we compare the effect of different 3D representations of fragment center under SE(3)-equivariant molecule local frame proposed in Section 3.3.2. We explore the use of SE(3)-invariant Cartesian coordinates instead of SE(3)-invariant spherical coordinates used in Section 3.3.3. From the result in Table 3, we can see that using spherical coordinates can achieve better binding affinity and chemical properties. By using spherical coordinates, the distances and angles are constrained to a smaller region, which makes the language model easier to learn structure correlations.

Then, we show that fragment-based tokenization is crucial to achieving better generation results. Specifically, we try to generate molecules atom-by-atom instead of using fragments. In this setting, we do not need to build fragment local frames, and rotation vectors do not exist in converted sequences. Results in Table 4 show that fragment-based generation can achieve much better performance on binding affinity and most drug-likeness properties, which validates the significance of fragmentation.

Finally, we compare different ways to incorporate protein pocket information into the model. Specifically, we convert protein structures to sequences in the same way as atom-based tokenization of small molecules. Then, we preappend the tokenized protein sequence to the corresponding ligand sequence and feed it into the language model. Results in Table 5 show that extracting protein node embeddings and integrating them into the language model via cross-attention can more effectively capture the interaction between proteins and ligands.

Table 3: Generation performance between using invariant Cartesian coordinates and spherical coordinates representations of fragment centers.

Methods	Vina Score (↓)	QED (†)	SA (†)	Lipinski (†)	Diversity (†)
Frag2Seq-Invariant Coordinates	-7.242 ± 2.11	0.636 ± 0.16	0.637 ± 0.10	4.974 ± 0.17	0.714 ± 0.09
Frag2Seq-Spherical Coordinates	-7.366 \pm 1.96	0.645 ± 0.15	0.642 ± 0.11	4.989 ± 0.11	0.711 ± 0.07

Table 4: Generation performance between using atom-by-atom and fragment-by-fragment manners.

Methods	Vina Score (↓)	QED (↑)	SA (↑)	Lipinski (†)	Diversity (↑)
Frag2Seq-Atom	-6.895 ± 1.42	0.484 ± 0.22	$egin{array}{l} {f 0.683 \pm 0.11} \ 0.642 \pm 0.11 \end{array}$	4.677 ± 0.50	0.737 ± 0.19
Frag2Seq-Fragment	-7.366 ± 1.96	0.645 ± 0.15		4.989 ± 0.11	0.711 ± 0.07

Table 5: Generation performance between different ways to incorporate protein information.

Methods	Vina Score (↓)	QED (†)	SA (†)	Lipinski (†)	Diversity (†)
Frag2Seq-Protein Seq	-6.646 ± 1.64	0.605 ± 0.17	0.691 ± 0.13	4.968 ± 0.18	0.493 ± 0.39
Frag2Seq-ESM-IF1	- 7.366 \pm 1.96	0.645 ± 0.15	0.642 ± 0.11	4.989 ± 0.11	0.711 ± 0.07

A.5 GENERATION EFFICIENCY ANALYSIS

In this section, we compare the generation efficiency of our method and other representative baseline methods. We use a single NVIDIA 2080Ti GPU and a batch size of 10. The results in Table 6 show that our method exhibits better sampling efficiency than other autoregressive and diffusion-based models.

Table 6: Generation efficiency comparison among autoregressive methods, diffusion methods, and our fragment-based LM method.

Methods	Parameters	Memory	Sample/second
3D-SBDD	1.2 M	3.4 GB	0.005
Pocket2Mol	3.7M	1.2 GB	0.008
DrugGPS	5.1M	2.5GB	0.73
TargetDiff	2.8M	1.8 GB	0.01
Frag2Seq	134.3M	2.2GB	2.0

B DERIVATION OF ROTATION VECTOR BETWEEN FRAGMENT AND MOLECULE FRAMES

In Section 3.3.2, we obtain the rotation matrix $R_{g\to m}$ between fragment and molecule local frames. Then, we can derive the more compact rotation vector representation. Specifically, we can obtain the rotation angle ψ by

$$\psi = \cos^{-1}(\frac{tr(R_{g\to m}) - 1}{2}),$$
 (9)

where $tr(\cdot)$ denote the trace of a matrix. Suppose $R_{{\mathfrak g} o {\mathfrak m}}$ has the following form

$$R_{\mathfrak{g}\to\mathfrak{m}} = \begin{bmatrix} r_{11} & r_{12} & r_{13} \\ r_{21} & r_{22} & r_{23} \\ r_{31} & r_{32} & r_{33} \end{bmatrix},\tag{10}$$

the rotation axis $\mathbf{a} = (a_x, a_y, a_z)$ can be obtained by

$$a_x = (r_{32} - r_{23})/2\sin\psi,\tag{11}$$

$$a_y = (r_{13} - r_{31})/2\sin\psi,\tag{12}$$

$$a_z = (r_{21} - r_{12})/2\sin\psi. \tag{13}$$

Then, we can calculate rotation vector $\mathbf{m} = (m_x, m_u, m_z)$ via $\mathbf{m} = \psi \mathbf{a}$.

C PROOFS

C.1 Proof of Lemma 3.2

Lemma (Canonical Ordering for 3D Molecular Graph Isomorphism). Let $\mathcal{M}_1 = (V_1, Z_1)$ and $\mathcal{M}_2 = (V_2, Z_2)$ be two 3D molecular graphs following Def. 3.1. Let $\mathbf{L} : \mathcal{M} \to \mathcal{L}$ be a function that maps a molecule $\mathcal{M} \in \mathcal{M}$, the set of all finite 3D molecular graphs, to its canonical order $\mathbf{L}(\mathcal{M}) \in \mathcal{L}$, the set of all possible canonical orders, as produced by the canonical SMILES. Then the following equivalence holds:

$$L(\mathcal{M}_1) = L(\mathcal{M}_2) \Leftrightarrow \mathcal{M}_1 \cong_{3D} \mathcal{M}_2$$

where $\mathcal{M}_1 \cong_{3D} \mathcal{M}_2$ denotes that \mathcal{M}_1 and \mathcal{M}_2 are 3D isomorphic.

Proof. We first prove the equivalence from right to left.

Given that $\mathcal{M}_1 \cong_{3D} \mathcal{M}_2$, from Def. 3.1, there exists a bijection $b: ver(\mathcal{M}_1) \to ver(\mathcal{M}_2)$ such that for every atom in \mathcal{M}_1 indexed $i, z_i^{\mathcal{M}_1} = z_{b(i)}^{\mathcal{M}_2}$, and there exists a 3D transformation $\tau \in SE(3)$ such that $v_i^{\mathcal{M}_1} = \tau(v_{b(i)}^{\mathcal{M}_2})$. Therefore, \mathcal{M}_2 is a rotated and translated instance of \mathcal{M}_1 . In this case, \mathcal{M}_1 and \mathcal{M}_2 has identical molecular structure. Canonical SMILES (O'Boyle, 2012; Weininger et al., 1989) provides a unique string representation for a given molecular structure. We leave out the proof for the rigor of the canonical SMILES algorithm, which has been provided by O'Boyle (2012). Thus for the canonical SMILES string of \mathcal{M}_1 and \mathcal{M}_2 , s_1 and s_2 , we have $s_1 = s_2$. Since $L(\mathcal{M}_1)$ and $L(\mathcal{M}_2)$ are the ordering in s_1 and s_2 , respectively, we have $L(\mathcal{M}_1) = L(\mathcal{M}_2)$.

Next we prove the equivalence from left to right. For two 3D molecular graphs $L(\mathcal{M}_1)$ and $L(\mathcal{M}_2)$, we know $L(\mathcal{M}_1) = L(\mathcal{M}_2)$. According to the canonical SMILES properties, if two molecules are not identical in structure, they are guaranteed to receive different canonical SMILES strings. Therefore, since $L(\mathcal{M}_1) = L(\mathcal{M}_2)$, \mathcal{M}_1 and \mathcal{M}_2 must be identical in structure. Then there exists bijection $b: ver(\mathcal{M}_1) \to ver(\mathcal{M}_2)$ such that $\mathbf{z}_i^{\mathcal{M}_1} = \mathbf{z}_{b(i)}^{\mathcal{M}_2}$ for every atom in \mathcal{M}_1 indexed i. Meanwhile, in this case, \mathcal{M}_2 can be derived from \mathcal{M}_1 after certain homogeneous 3D transformation under the right-handed Cartesian coordinate system, i.e., SE(3) transformation. An arbitrary rigid transformation in SE(3) can be separated into two parts, a translation and a rigid rotation. Let the translation and rotation needed be represented as τ_1, τ_2 . SE(3) is a Lie group and satisfies the axioms that the set is closed under the binary operation. $\tau_1, \tau_2 \in SE(3)$, thus $\tau_1\tau_2 \in SE(3)$. Let $\tau' = \tau_1\tau_2 \in SE(3)$. Therefore, there exist a 3D transformation $\tau' \in SE(3)$ such that $v_i^{\mathcal{M}_1} = \tau'(v_{b(i)}^{\mathcal{M}_2})$. Consequently, $\mathcal{M}_1 \cong_{3D} \mathcal{M}_2$.

C.2 PROOF OF LEMMA 3.3

Lemma. Let $\mathcal{M} = (V, Z)$ be a 3D molecular graph with node type vector z and node coordinate matrix V. Let \mathfrak{m} be equivariant local frames of \mathcal{M} built based on the first three non-collinear fragment centers in $L(\mathcal{M})$ and \mathfrak{g} be equivariant local frames of any fragment \mathcal{G}_i built based on

the first three non-collinear atoms in $L(\mathcal{G}_i)$. $f(\cdot)$ is our function that maps 3D coordinate matrix V of \mathcal{M} to spherical representations \mathbf{S} under the molecule local frame \mathfrak{m} . $g(\cdot,\cdot)$ is the function that maps the molecule local frame \mathfrak{m} and fragment local frame \mathfrak{g} to rotation vectors \mathbf{m} . Then for any 3D transformation $\tau \in SE(3)$, we have $f(V) = f(\tau(V))$ and $g(\mathfrak{m},\mathfrak{g}) = g(\tau(\mathfrak{m},\mathfrak{g}))$. Given spherical representations $\mathbf{S} = f(V)$ and rotation vectors $\mathbf{m} = g(\mathfrak{m},\mathfrak{g})$, there exist a transformation $\tau \in SE(3)$, such that $f^{-1}(\mathbf{S}) = \tau(V)$ and $g^{-1}(\mathbf{m}) = \tau(\mathfrak{m},\mathfrak{g})$.

Proof. We first prove the SE(3)-invariance of the spherical representations of fragment center under molecule local frame, then prove the rotation representations between the fragment and molecule local frames are also SE(3)-invariant.

To simplify the proof, we assume that the molecule is centered first by moving the first atom to the origin. Let ℓ_1 , ℓ_2 , and ℓ_m be the indices of the first three non-collinear fragment centers in \mathcal{M} , and the molecule local frame $\mathfrak{m}=(x,y,z)$ is calculated as

$$egin{aligned} & oldsymbol{x} = \operatorname{normalize}(oldsymbol{v}_{\ell_2} - oldsymbol{v}_{\ell_1}), \ & oldsymbol{y} = \operatorname{normalize}\left((oldsymbol{v}_{\ell_m} - oldsymbol{v}_{\ell_1}) \times oldsymbol{x}\right), \ & oldsymbol{z} = oldsymbol{x} \times oldsymbol{y}, \end{aligned}$$

where normalize(·) denotes normalizing input vectors into unit vectors. Given any SE(3) transformation τ containing rotation matrix R and translation vector t, we have transformed coordinate $v'_i = \tau(v_i) = Rv_i + t$. Then, we can apply this transformation to the vectors in Equation (14) to obtain the transformed basis vectors for the molecule local frame. Specifically,

$$\mathbf{x}' = \text{normalize}(R\mathbf{v}_{\ell_{2}} + \mathbf{t} - (R\mathbf{v}_{\ell_{1}} + \mathbf{t})) = R(\text{normalize}(\mathbf{v}_{\ell_{2}} - \mathbf{v}_{\ell_{1}})) = R\mathbf{x},
\mathbf{y}' = \text{normalize}\left((R\mathbf{v}_{\ell_{m}} + \mathbf{t} - (R\mathbf{v}_{\ell_{1}} + \mathbf{t})) \times \mathbf{x}'\right),
= \text{normalize}\left(R\left((\mathbf{v}_{\ell_{m}} - \mathbf{v}_{\ell_{1}}) \times \mathbf{x}\right)\right),
= R(\text{normalize}\left((\mathbf{v}_{\ell_{m}} - \mathbf{v}_{\ell_{1}}) \times \mathbf{x}\right)\right),
= R\mathbf{y},
\mathbf{z}' = \mathbf{x}' \times \mathbf{y}' = R\mathbf{x} \times R\mathbf{y} = R(\mathbf{x} \times \mathbf{y}) = R\mathbf{z}.$$
(15)

So, the new molecule local frame is subject to the same transformation. Then, for spherical coordinates of any fragment center $f(V)_{\ell_i}$ that is represented as

$$d_{\ell_{i}} = ||\boldsymbol{v}_{\ell_{i}} - \boldsymbol{v}_{\ell_{1}}||_{2},$$

$$\theta_{\ell_{i}} = \arccos\left((\boldsymbol{v}_{\ell_{i}} - \boldsymbol{v}_{\ell_{1}}) \cdot \boldsymbol{z}/d_{\ell_{i}}\right),$$

$$\phi_{\ell_{i}} = \operatorname{atan2}\left((\boldsymbol{v}_{\ell_{i}} - \boldsymbol{v}_{\ell_{1}}) \cdot \boldsymbol{y}, (\boldsymbol{v}_{\ell_{i}} - \boldsymbol{v}_{\ell_{1}}) \cdot \boldsymbol{x}\right),$$

$$(16)$$

we can derive the transformed spherical coordinate as

$$d'_{\ell_{i}} = ||R\boldsymbol{v}_{\ell_{i}} + \boldsymbol{t} - (R\boldsymbol{v}_{\ell_{1}} + \boldsymbol{t})||_{2} = ||R(\boldsymbol{v}_{\ell_{i}} - \boldsymbol{v}_{\ell_{1}})||_{2} = ||\boldsymbol{v}_{\ell_{i}} - \boldsymbol{v}_{\ell_{1}}||_{2} = d_{\ell_{i}},$$

$$d'_{\ell_{i}} = \arccos\left((R\boldsymbol{v}_{\ell_{i}} + \boldsymbol{t} - (R\boldsymbol{v}_{\ell_{1}} + \boldsymbol{t})) \cdot \boldsymbol{z}'/d'_{\ell_{i}}\right) = \arccos\left(R\left(\boldsymbol{v}_{\ell_{i}} - \boldsymbol{v}_{\ell_{1}}\right) \cdot R\boldsymbol{z}/d_{\ell_{i}}\right) = \theta_{\ell_{i}},$$

$$\phi'_{\ell_{i}} = \operatorname{atan2}\left((R\boldsymbol{v}_{\ell_{i}} + \boldsymbol{t} - (R\boldsymbol{v}_{\ell_{1}} + \boldsymbol{t})) \cdot \boldsymbol{y}', (R\boldsymbol{v}_{\ell_{i}} + \boldsymbol{t} - (R\boldsymbol{v}_{\ell_{1}} + \boldsymbol{t})) \cdot \boldsymbol{x}'\right),$$

$$= \operatorname{atan2}\left(R\left(\boldsymbol{v}_{\ell_{i}} - \boldsymbol{v}_{\ell_{1}}\right) \cdot R\boldsymbol{y}, R\left(\boldsymbol{v}_{\ell_{i}} - \boldsymbol{v}_{\ell_{1}}\right) \cdot R\boldsymbol{x}\right),$$

$$= \operatorname{atan2}\left((\boldsymbol{v}_{\ell_{i}} - \boldsymbol{v}_{\ell_{1}}) \cdot \boldsymbol{y}, (\boldsymbol{v}_{\ell_{i}} - \boldsymbol{v}_{\ell_{1}}) \cdot \boldsymbol{x}\right),$$

$$= \phi_{\ell_{i}}.$$

$$(17)$$

Thus, we show that $f(V) = f(\tau(V))$. Conversely, given spherical coordinates $(d_{\ell_i}, \theta_{\ell_i}, \phi_{\ell_i})$ for fragment center ℓ_i , we can obtain local Cartesian coordinates through the inverse function $f^{-1}(\cdot)$ as

$$[d_{\ell_i}\sin(\theta_{\ell_i})\cos(\phi_{\ell_i}), d_{\ell_i}\sin(\theta_{\ell_i})\sin(\phi_{\ell_i}), d_{\ell_i}\cos(\theta_{\ell_i})]. \tag{18}$$

Then, we can reconstruct the original coordinates of fragment centers by applying the SE(3) transformation $(R_{m\to w}, t_{m\to w})$ between the molecule local frame and the world frame, which is derived in Section 3.3.2. Formally,

$$\boldsymbol{v}_{\ell_i} = R_{\mathsf{m} \to \mathsf{w}} f^{-1}(\boldsymbol{S})^T + \boldsymbol{t}_{\mathsf{m} \to \mathsf{w}}. \tag{19}$$

So, there exist a transformation $\tau \in SE(3)$, such that $f^{-1}(S) = \tau(V)$.

Next, we prove that the rotation vector \boldsymbol{m} between the molecule local frame and the fragment local frame is also SE(3)-invariant. Suppose we have the transformation $(R_{\mathfrak{m}\to\mathfrak{w}},\boldsymbol{t}_{\mathfrak{m}\to\mathfrak{w}})$ between the molecule local frame \mathfrak{m} and the world frame \mathfrak{w} , and the transformation $(R_{\mathfrak{g}\to\mathfrak{w}},\boldsymbol{t}_{\mathfrak{g}\to\mathfrak{w}})$ between the fragment local frame \mathfrak{g} and the world frame. In Section 3.3.2, we derive the transformation $(R_{\mathfrak{g}\to\mathfrak{m}},\boldsymbol{t}_{\mathfrak{g}\to\mathfrak{m}})$ between the fragment local frame and the molecule local frame, such that

$$R_{\mathfrak{g}\to\mathfrak{m}} = R_{\mathfrak{m}\to\mathfrak{w}}^T R_{\mathfrak{g}\to\mathfrak{w}}, \quad t_{\mathfrak{g}\to\mathfrak{m}} = R_{\mathfrak{m}\to\mathfrak{w}}^T (t_{\mathfrak{g}\to\mathfrak{w}} - t_{\mathfrak{m}\to\mathfrak{w}}). \tag{20}$$

Given any SE(3) transformation τ containing rotation matrix R and translation vector t, we have

$$R_{\mathfrak{g}\to\mathfrak{m}} = (RR_{\mathfrak{m}\to\mathfrak{w}})^T (RR_{\mathfrak{g}\to\mathfrak{w}}), \tag{21}$$

$$= R_{\mathbf{m} \to \mathbf{w}}^T R^T R R_{\mathbf{q} \to \mathbf{w}}, \tag{22}$$

$$=R_{\mathbf{m}\to\mathbf{w}}^T I R_{\mathbf{g}\to\mathbf{w}},\tag{23}$$

$$=R_{\mathfrak{q}\to\mathfrak{m}}.$$

So we have $R_{\mathfrak{g}\to\mathfrak{m}}=\tau(R_{\mathfrak{g}\to\mathfrak{m}})$. Since $\boldsymbol{m}=g(\mathfrak{m},\mathfrak{g})$ is derived from $R_{\mathfrak{g}\to\mathfrak{m}}$, as described in Section 3.3.3, we also have $g(\mathfrak{m},\mathfrak{g})=g(\tau(\mathfrak{m},\mathfrak{g}))$.

Conversely, given a rotation vector m, we can convert it back to a rotation matrix. Specifically, let $m = \theta a$, where θ is the rotation angle and $a = (a_x, a_y, a_z)$ is the unit rotation axis. Then, we can construct the skew-symmetric matrix K from a such that

$$K = \begin{bmatrix} 0 & -a_z & a_y \\ a_z & 0 & -a_x \\ -a_y & a_x & 0 \end{bmatrix}.$$
 (25)

Then, we apply Rodrigues' rotation formula to obtain rotation matrix $R_{q\to m}$ such that

$$R_{g\to m} = I + \sin(\theta)K + (1 - \cos(\theta))K^2. \tag{26}$$

Then, we have $R_{\mathfrak{g}\to\mathfrak{w}}=R_{\mathfrak{m}\to\mathfrak{w}}R_{\mathfrak{g}\to\mathfrak{m}}$. From Equation (7), we can obtain $\boldsymbol{t}_{\mathfrak{g}\to\mathfrak{m}}$ and then we can have $\boldsymbol{t}_{\mathfrak{g}\to\mathfrak{w}}=R_{\mathfrak{m}\to\mathfrak{w}}\boldsymbol{t}_{\mathfrak{g}\to\mathfrak{m}}+\boldsymbol{t}_{\mathfrak{m}\to\mathfrak{w}}$. So, we show that there exist a SE(3) transformation $\tau=(R_{\mathfrak{m}\to\mathfrak{w}},\boldsymbol{t}_{\mathfrak{m}\to\mathfrak{w}})$, such that $g^{-1}(\boldsymbol{m})=\tau(\mathfrak{m},\mathfrak{g})$.

C.3 Proof of Theorem 3.4

First we establish a lemma and provide its proof.

Lemma C.1. Let $\mathcal{M}_1 = (V_1, Z_1)$ and $\mathcal{M}_2 = (V_2, Z_2)$ be two 3D molecular graphs, where \mathbf{z}_i is the node type vector and \mathbf{v}_i is the node coordinates of the molecule \mathcal{M}_i . There exists a bijection $b: ver(\mathcal{M}_1) \to ver(\mathcal{M}_2)$ such that for every atom in \mathcal{M}_1 indexed i, $\mathbf{z}_i^{\mathcal{M}_1} = \mathbf{z}_{b(i)}^{\mathcal{M}_2}$. Let $\mathbf{L}(\mathcal{M})$ be the canonical order of molecule \mathcal{M} . For the fragments $\{\mathcal{G}_i\}_{i=1}^k$ of \mathcal{M} , we construct canonical order $\mathbf{L}(\mathcal{M})$ for the k fragments, ℓ_1, \cdots, ℓ_k , specifically by the order of a fragment's first-ranked atom. Let ℓ_i and ℓ_i' denote the indexes of the fragment labeled i correspondingly in $\mathbf{L}(\mathcal{M}_1)$ and $\mathbf{L}(\mathcal{M}_2)$, respectively. Let $f \circ g$ be a surjective function that maps a 3D molecule \mathcal{M} to its spherical representation and rotation vector (S, m) under the equivariant molecule local frame, and between molecule local frame and fragment local frame, respectively, following Lemma 3.3. Then the following equivalence holds:

for
$$i = 1, \dots, k, f \circ g(\mathcal{M}_1)_{\ell_i} = f \circ g(\mathcal{M}_2)_{\ell'_i} \iff \mathcal{M}_1 \cong_{3D} \mathcal{M}_2$$

where $\mathcal{M}_1 \cong_{3D} \mathcal{M}_2$ denotes that \mathcal{M}_1 and \mathcal{M}_2 are 3D isomorphic.

Proof. From Def. 3.1, we know

$$\mathcal{M}_1 \cong_{3D} \mathcal{M}_2 \iff \left\{ \begin{array}{l} \text{there exists bijection } b: ver(\mathcal{M}_1) \rightarrow ver(\mathcal{M}_2) \ s.t. \forall i, \boldsymbol{z}_i^{\mathcal{M}_1} = \boldsymbol{z}_{b(i)}^{\mathcal{M}_2}, \text{ and there exists 3D transformation } \tau \in SE(3) \text{ such that } \boldsymbol{v}_{\ell_i'}^{\mathcal{M}_2} = \tau(\boldsymbol{v}_{\ell_i}^{\mathcal{M}_1}), \end{array} \right.$$

for all i. Note that since the fragmentation process is unique, deterministic, and linear, for fragments $\{\mathcal{G}_i\}_{i=1}^k$ of \mathcal{M} , $\{\mathcal{G}_i\}_{i=1}^k \equiv \mathcal{M}$. Thus fragmentation does not affect any properties. Thus it's sufficient to prove the equivalence of the two statements on right side with

for
$$i = 1, \dots, k, f \circ g(\mathcal{M}_1)_{\ell_i} = f \circ g(\mathcal{M}_2)_{\ell'_i}$$
.

Here, the first statement on the right holds by definition. For the second condition, we establish $\tau(v_{\ell_i}) = Rv_{\ell_i} + t$. Here R is a rotation matrix, and t is a translation vector.

Following the proof of Lemma 3.3 in Appendix C.2, for any 3D transformation $\tau \in SE(3)$, we have $f(V) = f(\tau(V))$ and $g(\mathfrak{m},\mathfrak{g}) = g(\tau(\mathfrak{m},\mathfrak{g}))$. Thus if there exists 3D transformation $\tau \in SE(3)$ such that $\boldsymbol{v}_{\ell_i'}^{\mathcal{G}_1} = \tau(\boldsymbol{v}_{\ell_i}^{\mathcal{M}_1})$, there exists 3D transformation $\tau \in SE(3)$ such that $\boldsymbol{v}_{\ell_i'}^{\mathcal{G}_1,\mathcal{M}_2} = \tau(\boldsymbol{v}_{\ell_i}^{\mathcal{G}_1,\mathcal{M}_1})$ for $i = 1, \dots, k$, and then

$$f \circ g(\mathcal{M}_1)_{\ell_i} = (S_1, m_1) = (S_2, m_2) = f \circ g(\mathcal{M}_2)_{\ell'_i}$$

for $i = 1, \dots, k$. This proves one direction of the equivalence.

Also following the proof of Lemma 3.3 in Appendix C.2, given spherical representations S=f(V) and rotation vectors $\boldsymbol{m}=g(\mathfrak{m},\mathfrak{g})$, there exist a transformation $\tau\in SE(3)$, such that $f^{-1}(S)=\tau(V)$ and $g^{-1}(\boldsymbol{m})=\tau(\mathfrak{m},\mathfrak{g})$. For $i=1,\cdots,k$, if we have $f\circ g(\mathcal{M}_1)_{\ell_i}=(S_1,\boldsymbol{m}_1)=(S_2,\boldsymbol{m}_2)=f\circ g(\mathcal{M}_2)_{\ell_i'}$, there exist a transformation $\tau\in SE(3)$, such that $f^{-1}(S_2)=\tau(v_2)$ and $g^{-1}(\boldsymbol{m})=\tau(\mathfrak{m}_2,\mathfrak{g}_2)$. Similarly, $f^{-1}(S_1)=\tau'(v_1)$ for $\tau'\in SE(3)$, and thus $\tau'(v_1)=f^{-1}(S_1)=f^{-1}(S_2)=\tau(v_2)$. Since SE(3) is a Lie group satisfying the axioms that the set is closed under the binary operation, and that for every element in SE(3), there is an identity inverse. Let the inverse identity of τ be τ^{-1} . Then $\tau^{-1}\tau(v_2)=\tau^{-1}\tau'(v_1)$, and thus $v_2=\tau''(v_1)$ with $\tau''=\tau^{-1}\tau'\in SE(3)$ for $i=1,\cdots,k$. This proves the other direction of the equivalence.

Therefore, we show that $\mathcal{M}_1 \cong_{3D} \mathcal{M}_2 \iff \forall i, f \circ g(\mathcal{M}_1)_{\ell_i} = f \circ g(\mathcal{M}_2)_{\ell'_i}$ holds. \square

Then we prove Theorem 3.4.

Theorem (Bijective mapping). Following Def. 3.1, let $\mathcal{M}_1 = (V_1, Z_1)$ and $\mathcal{M}_2 = (V_2, Z_2)$ be two 3D molecular graphs. Let $\mathbf{L}(\mathcal{M})$ be the canonical order for \mathcal{M} and $f(\cdot)$ and $g(\cdot, \cdot)$ be the functions following Lemma 3.3. Let the fragment-position vector for a molecule fragment \mathcal{G}_i be $\mathbf{x}_i^* = [s_i, d_i, \theta_i, \phi_i, m_{xi}, m_{yi}, m_{zi}]$, where the vector elements are derived from $f(\cdot)$ and $g(\cdot, \cdot)$ as predefined. For the fragments $\{\mathcal{G}_i\}_{i=1}^k$ of \mathcal{M} , we construct canonical order $\mathbf{L}(\mathcal{M})$ for the k fragments, ℓ_1, \dots, ℓ_k , specifically by the order of a fragment's first-ranked atom. We define Frag2Seq: $\mathcal{M} \to \mathcal{U}$, which maps a molecule $\mathcal{M} \in \mathcal{M}$ to its sequence representation $U \in \mathcal{U}$, the set of all possible sequence representations, as

$$Frag2Seq(\mathcal{M}) = concat(\boldsymbol{x}_{\ell_1}^*, \cdots, \boldsymbol{x}_{\ell_k}^*),$$

where $concat(\cdot)$ concatenates elements as a sequence. Then $Frag2Seq(\cdot)$ is a surjective function, and the following equivalence holds:

$$Frag2Seq(\mathcal{M}_1) = Frag2Seq(\mathcal{M}_2) \Leftrightarrow \mathcal{M}_1 \cong_{3D} \mathcal{M}_2,$$

where $\mathcal{M}_1 \cong_{3D} \mathcal{M}_2$ denotes \mathcal{M}_1 and \mathcal{M}_2 are 3D isomorphic. If we allow rounding up spherical coordinate and rotation vector values to $\geq b$ decimal places, then the surjectivity and equivalence still hold, only molecules \mathcal{M}_1 and \mathcal{M}_2 are $(|10^{-b}|/2)$ -constrained 3D isomorphic.

Proof. First, we prove that Frag2Seq : $\mathcal{M} \to \mathcal{U}$ is a surjective function. Given the definition

$$\operatorname{Frag2Seq}(\mathcal{M}) = \operatorname{concat}(\boldsymbol{x}_{\ell_1}^*, \cdots, \boldsymbol{x}_{\ell_k}^*),$$

where $\boldsymbol{x}_i^* = [s_i, d_i, \theta_i, \phi_i, m_{xi}, m_{yi}, m_{zi}]$, we need to prove that all operations are deterministic. concat(·) and s_i are defined to be deterministic, and following Lemma C.1, $d_i, \theta_i, \phi_i, m_{xi}, m_{yi}, m_{zi}$ are derived from $f \circ g$, which is a function. $\boldsymbol{L}(\mathcal{M})$ outputs \mathcal{M} 's canonical order, which is deterministic from the canonical SMILES algorithm. Therefore, Frag2Seq: $\mathcal{M} \to \mathcal{U}$ is a well-defined function; given a 3D molecule, we can uniquely construct a 1D sequence from Frag2Seq.

Next we prove Frag2Seq's surjectivity. Given any output sequence $q \in \mathcal{U}$ of Frag2Seq, the sequence is in the format

1135 1136 1137

1134

```
q = concat([s_1, d_1, \theta_1, \phi_1, m_{x1}, m_{v1}, m_{z1}], ..., [s_k, d_k, \theta_k, \phi_k, m_{xk}, m_{vk}, m_{zk}]).
```

1138 1139

For each fragment in q and its vector $[d_i, \theta_i, \phi_i, m_{xi}, m_{yi}, m_{zi}]$, we follow Lemma 3.3's derivations. Given the surjectivity of the spherical representation function f, rotation vector function g, and the defined f^{-1}, g^{-1} , there must be a unique $\mathcal{M} = (V, Z) \in \mathcal{M}$ where

1140 1141

$$[d_1, \theta_1, \phi_1, m_{x1}, m_{y1}, m_{z1}], ..., [d_k, \theta_k, \phi_k, m_{xk}, m_{yk}, m_{zk}] = f \circ g(\mathcal{M}).$$

1142 1143

Therefore, \forall output sequence $q \in \mathcal{U}$ there exists

$$\mathcal{M} = (V, Z) \in \mathcal{M}$$
 s.t. $q = \operatorname{Frag2Seq}(\mathcal{M}),$

1144 1145 1146

i.e., Frag2Seq is surjective; given a sequence output of Frag2Seq, we can uniquely reconstruct a 3D molecule.

1147 1148 1149

Since all the above proof does not involve numerical comparisons and 3D isomorphic, they also hold if we allow rounding up spherical coordinate and rotation vector values to $\geq b$ decimal places.

1150 1151

1152

1153

Now we prove the equivalence $\operatorname{Frag2Seq}(\mathcal{M}_1) = \operatorname{Frag2Seq}(\mathcal{M}_2) \Leftrightarrow \mathcal{M}_1 \cong_{3D} \mathcal{M}_2$, starting from right to left. We also cover the constrained case where we allow rounding up values to $\geq b$ decimal places. When a number is truncated after b decimal places, according to the rounding principle, the

1154 1155

maximum error caused is $\epsilon \leq \frac{|10^{-b}|}{2}$. If $\mathcal{M}_1 \cong_{3D} \mathcal{M}_2$ (or $\mathcal{M}_1 \cong_{3D-\frac{|10^{-b}|}{2}} \mathcal{M}_2$), *i.e.*, molecules \mathcal{M}_1 and \mathcal{M}_2 are 3D isomorphic (or $(|10^{-b}|/2)$ -constrained 3D isomorphic), then from Lemma 3.2

1156 we know the canonical forms $L(\mathcal{M}_1) = L(\mathcal{M}_2)$. For the fragments $\{\mathcal{G}_i\}_{i=1}^k$ of \mathcal{M} , we construct 1157 canonical order $L(\mathcal{M})$ for the k fragments, ℓ_1, \dots, ℓ_k , specifically by the order of a fragment's first-ranked atom. Let ℓ_i and ℓ'_i denote the indexes of the fragment labeled i correspondingly in 1158 1159 $L(\mathcal{M}_1)$ and $L(\mathcal{M}_2)$, respectively. Since molecules \mathcal{M}_1 and \mathcal{M}_2 are 3D isomorphic (or $(|10^{-b}|/2)$ -

constrained 3D isomorphic), from Def.3.1 we know $\forall i$ of $\{\mathcal{G}_i\}_{i=1}^k$, $s_{\ell_i} = s_{\ell'_i}$; and from Lemma C.1 1160 1161

we know for $i=1,\cdots,k,$ $f\circ g(\mathcal{M}_1)_{\ell_i}=f\circ g(\mathcal{M}_2)_{\ell_i'}$ (or satisfies with $\frac{|10^{-b}|}{2}$ error range allowed

1162 for each numerical value). Thus, we have

1163 Frag2Seq(\mathcal{M}_1) 1164

$$=\operatorname{concat}(\boldsymbol{x}_{\ell_1}^*,\cdots,\boldsymbol{x}_{\ell_k}^*)$$

$$= \operatorname{concat}_{s_i(\mathcal{G}_i),\mathcal{G}_i \in \mathcal{M}_1, d_i, \theta_i, \phi_i, m_{xi}, m_{yi}, m_{zi} \in f \circ g(\mathcal{M}_1), i=1, \dots k} ([s_{\ell_i}, d_{\ell_i}, \theta_{\ell_i}, \phi_{\ell_i}, m_{x\ell_i}, m_{y\ell_i}, m_{z\ell_i}])$$

$$= \operatorname{concat}_{s_{i}(\mathcal{G}_{i}), \mathcal{G}_{i} \in \mathcal{M}_{2}, d_{i}, \theta_{i}, \phi_{i}, m_{xi}, m_{vi}, m_{zi} \in f \circ g(\mathcal{M}_{2}), i=1, \dots k}([s_{\ell'_{i}}, d_{\ell'_{i}}, \theta_{\ell'_{i}}, \phi_{\ell'_{i}}, m_{x\ell'_{i}}, m_{y\ell'_{i}}, m_{z\ell'_{i}}])$$

 $= \operatorname{concat}(\boldsymbol{x}_{\ell_1'}^*, \cdots, \boldsymbol{x}_{\ell_\ell'}^*)$

1170 = Frag2Seq(\mathcal{M}_2), 1171

where $s_i(\cdot)$ is the canonical SMILES string. Therefore, we have shown that if two molecules are 3D isomorphic (or within the round-up error range $\frac{|10^{-b}|}{2}$), their sequences resulting from Frag2Seq must be identical.

1178

1179

1180

1165 1166

1167

1168

1169

1172

1173

Finally, we prove the equivalence from left to right. We provide proof by contradiction. Given that $\operatorname{Frag2Seq}(\mathcal{M}_1) = \operatorname{Frag2Seq}(\mathcal{M}_2)$, we assume that the molecules \mathcal{M}_1 and \mathcal{M}_2 are not 3D isomorphic (or not $\frac{|10^{-b}|}{2}$ -constrained 3D isomorphic). We denote with $\mathcal{M}_1=(V_1,Z_1)$ and $\mathcal{M}_2=$ (V_2, Z_2) . If \mathcal{M}_1 and \mathcal{M}_2 are not even isomorphic for Z_i , then from Def.3.1, there does not exist a node-to-node mapping from \mathcal{M}_1 to \mathcal{M}_2 , where each atom is identical in atom number. Then from Lemma 3.2, we know the canonical forms $L(\mathcal{M}_1) \neq L(\mathcal{M}_2)$. Thus for Frag2Seq (\mathcal{M}_1) =

1181 1182 1183

$$\operatorname{concat}_{s_i(\mathcal{G}_i),\mathcal{G}_i \in \mathcal{M}_1,d_i,\theta_i,\phi_i,m_{xi},m_{yi},m_{zi} \in f \circ g(\mathcal{M}_1),i=1,...k}([s_{\ell_i},d_{\ell_i},\theta_{\ell_i},\phi_{\ell_i},m_{x\ell_i},m_{y\ell_i},m_{z\ell_i}]),$$

1184

1186

1187

and Frag2Seq
$$(\mathcal{M}_2)$$
 =

1185

$$\mathsf{concat}_{s_i(\mathcal{G}_i),\mathcal{G}_i \in \mathcal{M}_2,d_i,\theta_i,\phi_i,m_{xi},m_{yi},m_{zi} \in f \circ g(\mathcal{M}_2),i=1,\dots k}([s_{\ell_i'},d_{\ell_i'},\theta_{\ell_i'},\theta_{\ell_i'},m_{x\ell_i'},m_{y\ell_i'},m_{z\ell_i'}]),$$

there must be at least one pair of $s_{\ell_i}, s_{\ell'_i}$ where $s_{\ell_i} \neq s_{\ell'_i}$. Therefore, Frag2Seq $(\mathcal{M}_1) \neq s_{\ell'_i}$ Frag2Seq(\mathcal{M}_2), which is a contradiction to the initial condition and ends the proof.

If \mathcal{M}_1 and \mathcal{M}_2 are isomorphic for Z_i , we continue with the following analyses. Let ℓ_i and ℓ_i' denote the indexes of the fragment labeled i correspondingly in $L(\mathcal{M}_1)$ and $L(\mathcal{M}_2)$, respectively. Let $f \circ g$ be the surjective function mapping a 3D graph to its spherical and rotation representations. Since \mathcal{M}_1 and \mathcal{M}_2 are not 3D isomorphic (or not even $\frac{|10^{-b}|}{2}$ -constrained 3D isomorphic), from Lemma C.1, we know there exists at least one

$$i \in \{1, \dots, k\}, s.t.f \circ g(\mathcal{M}_1)_{\ell_i} \neq f(\mathcal{M}_2)_{\ell'_i},$$

(or even with error range $\frac{|10^{-b}|}{2}$ allowed), otherwise, we would have

$$\forall i \in \{1, \dots, k\}, f(\mathcal{M}_1)_{\ell_i} = f(\mathcal{M}_2)_{\ell'_i} \Rightarrow \mathcal{M}_1 \cong_{3D} \mathcal{M}_2,$$

contradicting the above condition. Thus for Frag2Seq(\mathcal{M}_1) =

$$\operatorname{concat}_{s_i(\mathcal{G}_i),\mathcal{G}_i \in \mathcal{M}_1,d_i,\theta_i,\phi_i,m_{xi},m_{yi},m_{zi} \in f \circ g(\mathcal{M}_1),i=1,\dots k}([s_{\ell_i},d_{\ell_i},\theta_{\ell_i},\phi_{\ell_i},m_{x\ell_i},m_{y\ell_i},m_{z\ell_i}]),$$

and Frag2Seq(\mathcal{M}_2) =

$$\operatorname{concat}_{s_i(\mathcal{G}_i),\mathcal{G}_i \in \mathcal{M}_2,d_i,\theta_i,\phi_i,m_{xi},m_{yi},m_{zi} \in f \circ q(\mathcal{M}_2), i=1,\dots k}([s_{\ell'_i},d_{\ell'_i},\theta_{\ell'_i},\theta_{\ell'_i},m_{x\ell'_i},m_{y\ell'_i},m_{z\ell'_i}]),$$

at least one pair of spherical coordinates does not correspond, so there must be at least one pair of $(d_{\ell_i}, \theta_{\ell_i}, \phi_{\ell_i}, m_{x\ell_i}, m_{y\ell_i}, m_{z\ell_i})$ and $(d_{\ell'_i}, \theta_{\ell'_i}, \phi_{\ell'_i}, m_{x\ell'_i}, m_{y\ell'_i}, m_{z\ell'_i})$ where

$$(d_{\ell_i}, \theta_{\ell_i}, \phi_{\ell_i}, m_{x\ell_i}, m_{y\ell_i}, m_{z\ell_i}) \neq (d_{\ell'_i}, \theta_{\ell'_i}, \phi_{\ell'_i}, m_{x\ell'_i}, m_{y\ell'_i}, m_{z\ell'_i})$$

(or

$$\min(|d_{\ell_i}, \theta_{\ell_i}, \phi_{\ell_i}, m_{x\ell_i}, m_{y\ell_i}, m_{z\ell_i}| - |d_{\ell'_i}, \theta_{\ell'_i}, \theta_{\ell'_i}, m_{x\ell'_i}, m_{y\ell'_i}, m_{z\ell'_i}|) > \frac{|10^{-b}|}{2}).$$

Thus, $Frag2Seq(\mathcal{M}_1) \neq Frag2Seq(\mathcal{M}_2)$, which contradicts the initial condition. Therefore, we have shown that if two constructed sequences from Frag2Seq are identical, their corresponding molecules must be 3D isomorphic. This ends the proof.